



QUARTERLY INFORMATION

SEPTEMBER 30, 2023



FLRY
B3 LISTED NM



IBOVESPA B3

IBRX100 B3

ISEB3

Member of
Dow Jones
Sustainability Indices
Powered by the S&P Global CSA





(A free translation of the original in Portuguese)

Report on review of quarterly information

To the Board of Directors and Shareholders
Fleury S.A.

Introduction

We have reviewed the accompanying parent company and consolidated interim accounting information of Fleury S.A. ("Company"), included in the Quarterly Information Form (ITR) for the quarter ended September 30, 2023, comprising the balance sheet at that date and the statements of income and comprehensive income for the quarter and nine-month period then ended, and the statements of changes in equity and cash flows for the nine-month period then ended, and explanatory notes.

Management is responsible for the preparation of the parent company and consolidated interim accounting information in accordance with the accounting standard CPC 21 - "Interim Financial Reporting", of the Brazilian Accounting Pronouncements Committee (CPC) and International Accounting Standard (IAS) 34 - "Interim Financial Reporting" issued by the International Accounting Standards Board (IASB), as well as the presentation of this information in accordance with the standards issued by the Brazilian Securities Commission (CVM), applicable to the preparation of the Quarterly Information (ITR). Our responsibility is to express a conclusion on this interim accounting information based on our review.

Scope of review

We conducted our review in accordance with Brazilian and International Standards on Reviews of Interim Financial Information (NBC TR 2410 - "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", and ISRE 2410 - "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", respectively). A review of interim information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Brazilian and International Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

Conclusion on the interim information

Based on our review, nothing has come to our attention that causes us to believe that the accompanying parent company and consolidated interim accounting information included in the quarterly information referred to above has not been prepared, in all material respects, in accordance with CPC 21 and IAS 34 applicable to the preparation of the quarterly information and presented in accordance with the standards issued by the CVM.




Fleury S.A.

Other matters

Statements of value added

The quarterly information referred to above includes the parent company and consolidated statements of value added for the nine-month period ended September 30, 2023. These statements are the responsibility of the Company's management and are presented as supplementary information under IAS 34. These statements have been subjected to review procedures performed together with the review of the interim accounting information for the purpose of concluding whether they are reconciled with the interim accounting information and accounting records, as applicable, and if their form and content are in accordance with the criteria defined in the accounting standard CPC 09 - "Statement of Value Added". Based on our review, nothing has come to our attention that causes us to believe that these statements of value added have not been properly prepared, in all material respects, in accordance with the criteria established in this accounting standard, and consistent with the parent company and consolidated interim accounting information taken as a whole.

São Paulo, November 8, 2023


PricewaterhouseCoopers
Auditores Independentes Ltda.
CRC 2SP000160/O-5

DocuSigned by:
Marcelo Orlando
Signed By: MARCELO ORLANDO:05390848837
CPF: 05390848837
Signing Time: 10 November 2023 | 13:53 BRT

Marcelo Orlando
Contador CRC 1SP217518/O-7

Contents

Company information

Breakdown of capital	1
----------------------	---

Individual financial statements

Balance sheet - Assets	2
------------------------	---

Balance sheet - Liabilities	3
-----------------------------	---

Statement of income	5
---------------------	---

Statement of comprehensive income	6
-----------------------------------	---

Statement of cash flows (Indirect method)	7
---	---

Statement of changes in shareholders' equity

Statement of changes in shareholders' equity (DMPL) – 01/01/2023–09/30/2023	9
---	---

Statement of changes in shareholders' equity (DMPL) – 01/01/2022–09/30/2022	10
---	----

Statement of added value	11
--------------------------	----

Consolidated financial statements

Balance sheet - Assets	12
------------------------	----

Balance sheet - Liabilities	13
-----------------------------	----

Statement of income	15
---------------------	----

Statement of comprehensive income	16
-----------------------------------	----

Statement of cash flows (Indirect method)	17
---	----

Statement of changes in shareholders' equity

Statement of changes in shareholders' equity (DMPL) – 01/01/2023–09/30/2023	19
---	----

Statement of changes in shareholders' equity (DMPL) – 01/01/2022–09/30/2022	20
---	----

Statement of added value	21
--------------------------	----

Company information / Breakdown of capital

Quantity of shares (Unit)	Current quarter 09/30/2023
Paid-up capital	
Common	547,191,026
Preferred	0
Total	547,191,026
Treasury	
Common	384,976
Preferred	0
Total	384,976

Individual financial statements / Balance sheet -

Assets (In thousands of Reais)

Code of account	Account description	Current quarter 09/30/2023	Prior year 12/31/2022
1	Total assets	9,648,261	7,250,931
1.01	Current assets	1,666,927	2,048,906
1.01.01	Cash and cash equivalents	2,949	9,121
1.01.02	Interest earning bank deposits	641,731	1,174,965
1.01.02.01	Interest earning bank deposits measured at fair value through profit or loss	641,731	1,174,965
1.01.02.01.03	Securities	641,731	1,174,965
1.01.03	Accounts receivable	858,237	701,549
1.01.03.01	Clients	858,237	701,549
1.01.04	Inventories	63,675	68,994
1.01.06	Recoverable taxes	70,284	64,899
1.01.06.01	Current recoverable taxes	70,284	64,899
1.01.06.01.01	Recoverable taxes	10,982	12,797
1.01.06.01.02	IRPJ and CSLL recoverable	59,302	52,102
1.01.08	Other current assets	30,051	29,378
1.01.08.03	Other	30,051	29,378
1.01.08.03.04	Other Assets	30,051	29,378
1.02	Non-current assets	7,981,334	5,202,025
1.02.01	Long-term assets	81,245	66,175
1.02.01.01	Interest earning bank deposits measured at fair value through profit or loss	33,987	32,473
1.02.01.01.01	Fair value securities	33,987	32,473
1.02.01.10	Other non-current assets	47,258	33,702
1.02.01.10.03	Judicial Deposits	17,995	17,764
1.02.01.10.05	Other Assets	29,263	15,938
1.02.02	Investments	4,045,062	1,634,014
1.02.02.01	Ownership interest	4,045,062	1,634,014
1.02.02.01.02	Interest in subsidiaries	4,045,062	1,634,014
1.02.03	Property, plant and equipment	1,707,440	1,752,882
1.02.03.01	Construction in progress	812,531	833,379
1.02.03.02	Right-of-use in lease	894,909	919,503
1.02.04	Intangible assets	2,147,587	1,748,954
1.02.04.01	Intangible assets	2,147,587	1,748,954
1.02.04.01.02	Intangible	2,147,587	1,748,954

Individual financial statements/ Balance sheet -**Liabilities (In thousands of Reais)**

Code of account	Account description	Current quarter 09/30/2023	Prior year 12/31/2022
2	Total liabilities	9,648,261	7,250,931
2.01	Current liabilities	909,289	1,063,566
2.01.01	Social and labor charges	237,748	204,575
2.01.01.02	Labor obligations	237,748	204,575
2.01.02	Suppliers	267,609	283,544
2.01.02.01	Domestic suppliers	267,100	283,247
2.01.02.02	Foreign suppliers	509	297
2.01.03	Tax obligations	30,663	23,665
2.01.03.01	Federal tax obligations	12,179	10,878
2.01.03.01.01	Income tax and social contribution payable	0	327
2.01.03.01.02	Federal tax obligations	12,179	10,551
2.01.03.02	State tax obligations	67	0
2.01.03.03	Municipal tax obligations	18,417	12,787
2.01.04	Loans and financing	273,102	513,265
2.01.04.01	Loans and financing	6,880	12,051
2.01.04.01.01	In domestic currency	6,880	12,051
2.01.04.02	Debentures	97,435	348,081
2.01.04.03	Financing through lease	168,787	153,133
2.01.05	Other liabilities	100,167	38,517
2.01.05.02	Other	100,167	38,517
2.01.05.02.01	Dividends and interest on own capital payable	78,725	80
2.01.05.02.04	Accounts payable - Acquisition of companies	10,064	24,786
2.01.05.02.06	Other liabilities	11,378	13,651
2.02	Non-current liabilities	3,561,838	3,505,829
2.02.01	Loans and financing	3,020,927	3,055,385
2.02.01.02	Debentures	2,199,179	2,198,917
2.02.01.03	Financing through lease	821,748	856,468
2.02.02	Other liabilities	78,576	67,666
2.02.02.02	Other	78,576	67,666
2.02.02.02.03	Accounts payable - Acquisition of companies	76,923	63,642
2.02.02.02.04	Tax installments	1,653	4,024
2.02.03	Deferred taxes	452,749	366,215
2.02.03.01	Deferred income tax and social contribution	452,749	366,215
2.02.04	Provisions	9,586	16,563
2.02.04.01	Tax, social security, labor and civil provision	9,586	16,563
2.02.04.01.01	Tax provisions	18,891	21,465
2.02.04.01.02	Social security and labor provisions	20,438	24,790
2.02.04.01.04	Provisions Civil	5,029	4,428
2.02.04.01.05	Judicial deposits	-34,772	-34,120
2.03	Shareholders' equity	5,177,134	2,681,536
2.03.01	Realized capital	2,736,029	1,717,222
2.03.02	Capital reserves	1,915,413	603,212
2.03.02.04	Options granted	0	38,050
2.03.02.07	Capital reserve	1,915,413	565,162
2.03.04	Profit reserves	201,860	361,102
2.03.04.01	Legal reserve	148,616	148,616

Individual financial statements/ Balance sheet -

Liabilities (In thousands of Reais)

Code of account	Account description	Current quarter 09/30/2023	Prior year 12/31/2022
2.03.04.05	Profit retention reserve	24,838	187,291
2.03.04.09	Treasury shares	-9,213	-19,971
2.03.04.10	Reserve for investments	37,619	45,166
2.03.05	Retained earnings/losses	249,948	0
2.03.06	Equity valuation adjustments	73,884	0

Individual financial statements / Statement of

income (In thousands of Reais)

Code of account	Account description	Current quarter 07/01/2023–09/30/2023	Accumulated of the current year 01/01/2023–09/30/2023	Same quarter of the prior year 07/01/2022–09/30/2022	Accumulated of the prior year 01/01/2022–09/30/2022
3.01	Revenue from sales of goods and/or services	1,053,228	3,060,606	947,768	2,814,671
3.02	Cost of goods and/or services sold	-720,323	-2,128,245	-666,360	-1,963,573
3.03	Gross income (loss)	332,905	932,361	281,408	851,098
3.04	Operating expenses/revenues	-88,263	-327,339	-66,301	-230,509
3.04.01	Sales expenses	-9,626	-27,960	0	0
3.04.02	General and administrative expenses	-104,704	-384,673	-96,259	-281,147
3.04.04	Other operating revenues	-344	-5,413	7,669	16,235
3.04.06	Equity in net income of subsidiaries	26,411	90,707	22,289	34,403
3.05	Income (loss) before financial income (loss) and taxes	244,642	605,022	215,107	620,589
3.06	Financial income (loss)	-86,347	-254,833	-98,401	-247,768
3.06.01	Financial revenues	20,347	85,059	23,342	58,479
3.06.02	Financial expenses	-106,694	-339,892	-121,743	-306,247
3.07	Income (loss) before financial income (loss) and taxes	158,295	350,189	116,706	372,821
3.08	Income tax and social contribution	15,902	-7,711	-20,700	-95,865
3.08.01	Current	-16,727	-56,712	-42,244	-122,675
3.08.02	Deferred	32,629	49,001	21,544	26,810
3.09	Net income (loss) from continued operations	174,197	342,478	96,006	276,956
3.11	Income/loss for the period	174,197	342,478	96,006	276,956
3.99	Earnings per share - (Reais / Share)				
3.99.01	Basic earnings per share				
3.99.01.01	Common shares	0.35949	0.70676	0.30273	0.87331
3.99.02	Diluted earnings per share				
3.99.02.01	Common shares	0.35945	0.70669	0.30259	0.8729

Individual financial statements / Statement of comprehensive

income (In thousands of Reais)

Code of account	Account description	Current quarter 07/01/2023–09/30/2023	Accumulated of the current year 01/01/2023–09/30/2023	Same quarter of the prior year 07/01/2022–09/30/2022	Accumulated of the prior year 01/01/2022–09/30/2022
4.01	Net income for the period	174,197	342,478	96,006	276,956
4.03	Comprehensive income for the period	174,197	342,478	96,006	276,956

Individual financial statements / Statement of cash flows**(Indirect method) (in thousands of Reais)**

Code of account	Account description	Accumulated of the current year 01/01/2023–09/30/2023	Accumulated of the prior year 01/01/2022–09/30/2022
6.01	Net cash from operating activities	774,669	701,825
6.01.01	Cash generated in operations	1,038,160	1,006,559
6.01.01.01	Net income for the year	342,478	276,956
6.01.01.02	Income tax and social contribution	7,711	95,865
6.01.01.03	Financial revenues and expenses	337,522	300,533
6.01.01.04	Depreciation and amortization	342,013	289,525
6.01.01.05	Equity in net income of subsidiaries	-90,707	-34,403
6.01.01.06	Stock option plan	10,510	9,752
6.01.01.07	Formation of provision for tax, labor and civil risks	422	4,267
6.01.01.08	Estimated losses for disallowance and allowance for doubtful accounts	36,900	31,785
6.01.01.09	Profit sharing	51,829	42,054
6.01.01.10	Other	-518	-9,775
6.01.02	Changes in assets and liabilities	-189,435	-159,232
6.01.02.01	(Increase) decrease in accounts receivable	-193,588	-71,072
6.01.02.02	(Increase) decrease in inventories	5,319	-3,336
6.01.02.03	(Increase) decrease in recoverable taxes	-5,385	-11,221
6.01.02.04	(Increase) decrease in judicial deposits	-232	4,467
6.01.02.05	(Increase) decrease in other assets	-13,963	14,770
6.01.02.06	Increase (decrease) in suppliers	-15,935	-58,352
6.01.02.07	Increase (decrease) in salaries and charges payable	-8,926	-15,526
6.01.02.08	Increase (decrease) in tax liabilities	6,212	-5,371
6.01.02.09	Increase (decrease) in scheduling of tax payments	-1,258	-6,572
6.01.02.10	Increase (decrease) in other liabilities	38,321	-7,019
6.01.03	Other	-74,056	-145,502
6.01.03.01	Income tax and social contribution paid	-74,056	-145,502
6.02	Net cash from investment activities	-65,080	-703,642
6.02.01	Acquisition of property, plant and equipment and intangible assets	-209,453	-244,857
6.02.02	Sale of property, plant and equipment	0	6,650
6.02.03	Securities - funding and income	532,002	66,424
6.02.04	Payments for acquired companies less cash and cash equivalents	-53,195	-353,158
6.02.06	Acquisition of equity interest	0	-12,300
6.02.07	Paid-up capital in subsidiary	-334,434	-166,401
6.03	Net cash from financing activities	-715,761	-8,341
6.03.01	Funding through financing/debentures	0	700,000
6.03.02	(Principal) repayment of financing and debentures	-250,000	-169,688
6.03.03	Interest paid on financing and debentures	-250,828	-158,315
6.03.04	Financial commissions and other	-2,801	-2,819
6.03.05	Derivative financial instruments	0	-846
6.03.06	Lease	-193,081	-147,808
6.03.07	Capital increase	0	1,696
6.03.08	Dividends and/or interest on own capital	-13,880	-229,148
6.03.10	Operation - drawee risk	-5,171	-1,413
6.05	Increase (decrease) in cash and cash equivalents	-6,172	-10,158

Individual financial statements / Statement of cash flows (Indirect method)

(In thousands of reais)

Code of account	Account description	Accumulated of the current year	Accumulated of the prior year
		01/01/2023–09/30/2023	01/01/2022–09/30/2022
6.05.01	Opening balance of cash and cash equivalents	9,121	12,104
6.05.02	Closing balance of cash and cash equivalents	2,949	1,946

Individual financial statements / Statement of changes in shareholders' equity / DMPL - 01/01/2023–

09/30/2023 (In thousands of reais)

Code of account	Account description	Paid-up capital	Capital reserves, options granted and treasury shares	Profit reserves	Retained earnings or losses	Other comprehensive income	Shareholders' equity
5.01	Opening balances	1,717,222	583,241	381,073	0	0	2,681,536
5.03	Adjusted opening balances	1,717,222	583,241	381,073	0	0	2,681,536
5.04	Capital transactions with partners	1,018,807	1,322,959	-170,000	-92,530	73,884	2,153,120
5.04.01	Capital increases	170,111	0	-170,000	0	0	111
5.04.02	Expenditures with issuance of shares	-320	0	0	0	0	-320
5.04.03	Recognized options granted	0	114	0	0	0	114
5.04.05	Treasury shares sold	0	10,758	0	0	0	10,758
5.04.07	Interest on own capital	0	0	0	-92,530	0	-92,530
5.04.08	Acquisition of Company's interest	849,016	1,312,087	0	0	73,884	2,234,987
5.05	Total comprehensive income	0	0	0	342,478	0	342,478
5.05.01	Net income for the period	0	0	0	342,478	0	342,478
5.06.04	Investment retention	0	0	162,453	0	0	162,453
5.06.05	Retained earnings	0	0	-162,453	0	0	-162,453
5.07	Closing balances	2,736,029	1,906,200	211,073	249,948	73,884	5,177,134

Individual financial statements / Statement of changes in shareholders' equity / DMPL - 01/01/2022–

09/30/2022 (In thousands of reais)

Code of account	Account description	Paid-up capital	Capital reserves, options granted and treasury shares	Profit reserves	Retained earnings or losses	Other comprehensive income	Shareholders' equity
5.01	Opening balances	1,437,253	12,638	395,392	0	0	1,845,283
5.03	Adjusted opening balances	1,437,253	12,638	395,392	0	0	1,845,283
5.04	Capital transactions with partners	1,696	5,297	-214,329	0	0	-207,336
5.04.01	Capital increases	1,696	0	0	0	0	1,696
5.04.03	Recognized options granted	0	432	0	0	0	432
5.04.05	Treasury shares sold	0	4,865	0	0	0	4,865
5.04.06	Dividends	0	0	-214,329	0	0	-214,329
5.05	Total comprehensive income	0	0	0	276,956	0	276,956
5.05.01	Net income for the period	0	0	0	276,956	0	276,956
5.06.04	Retained earnings	0	0	-12,830	0	0	-12,830
5.06.05	Investment retention	0	0	12,830	0	0	12,830
5.07	Closing balances	1,438,949	17,935	181,063	276,956	0	1,914,903

Individual financial statements / Statement of added

value - (In thousands of reais)

Code of account	Account description	Accumulated of the current year	Accumulated of the prior year
		01/01/2023–09/30/2023	01/01/2022–09/30/2022
7.01	Revenues	3,271,881	3,029,885
7.01.01	Sale of goods, products and services	3,293,131	3,027,637
7.01.02	Other revenues	10,638	32,355
7.01.04	Formation/reversal of allowance for doubtful accounts	-31,888	-30,107
7.02	Inputs acquired from third parties	-1,265,501	-1,125,595
7.02.01	Cost of products, goods and services sold	-1,117,203	-1,047,545
7.02.02	Materials, energy, outsourced services and other	-146,820	-75,091
7.02.03	Loss/recovery of asset values	-1,478	-2,959
7.03	Gross added value	2,006,380	1,904,290
7.04	Retentions	-342,013	-289,525
7.04.01	Depreciation, amortization and depletion	-342,013	-289,525
7.05	Net added value produced	1,664,367	1,614,765
7.06	Added value received as transfer	179,909	95,523
7.06.01	Equity in net income of subsidiaries	90,707	34,403
7.06.02	Financial revenues	89,202	61,120
7.07	Total added value payable	1,844,276	1,710,288
7.08	Distribution of added value	1,844,276	1,710,288
7.08.01	Personnel	787,550	693,698
7.08.01.01	Direct remuneration	546,017	479,787
7.08.01.02	Benefits	194,139	176,061
7.08.01.03	F.G.T.S.	47,394	37,850
7.08.02	Taxes, duties and contributions	349,860	400,724
7.08.02.01	Federal	247,770	310,892
7.08.02.03	Municipal	102,090	89,832
7.08.03	Third-party capital remuneration	364,388	338,910
7.08.03.01	Interest	339,892	306,247
7.08.03.02	Rents	-1,610	9,682
7.08.03.03	Other	26,106	22,981
7.08.04	Remuneration of own capital	342,478	276,956
7.08.04.01	Interest on own capital	92,530	0
7.08.04.03	Retained earnings / Loss for the period	249,948	276,956

Consolidated financial statements / Balance sheet -**Assets (In thousands of Reais)**

Code of account	Account description	Current quarter 09/30/2023	Prior year 12/31/2022
1	Total assets	11,533,043	7,791,770
1.01	Current assets	2,838,559	2,391,404
1.01.01	Cash and cash equivalents	14,117	17,256
1.01.02	Interest earning bank deposits	962,521	1,292,234
1.01.02.01	Interest earning bank deposits measured at fair value through profit or loss	962,521	1,292,234
1.01.02.01.03	Securities	962,521	1,292,234
1.01.03	Accounts receivable	1,558,622	856,849
1.01.03.01	Clients	1,558,622	856,849
1.01.04	Inventories	135,196	96,576
1.01.06	Recoverable taxes	108,930	77,022
1.01.06.01	Current recoverable taxes	108,930	77,022
1.01.06.01.01	Recoverable taxes	16,989	14,757
1.01.06.01.02	IRPJ and CSLL recoverable	91,941	62,265
1.01.08	Other current assets	59,173	51,467
1.01.08.01	Non-current assets held for sale	0	14,968
1.01.08.03	Other	59,173	36,499
1.01.08.03.04	Other Assets	59,173	36,499
1.02	Non-current assets	8,694,484	5,400,366
1.02.01	Long-term assets	236,455	248,190
1.02.01.01	Interest earning bank deposits measured at fair value through profit or loss	121,674	121,641
1.02.01.01.01	Fair value securities	121,674	121,641
1.02.01.04	Accounts receivable	2,774	0
1.02.01.04.01	Clients	2,774	0
1.02.01.07	Deferred taxes	29,695	48,624
1.02.01.07.01	Deferred income tax and social contribution	29,695	48,624
1.02.01.10	Other non-current assets	82,312	77,925
1.02.01.10.03	Judicial deposits	25,461	24,160
1.02.01.10.05	Other Assets	56,851	53,765
1.02.02	Investments	68,260	44,080
1.02.02.01	Ownership interest	68,260	44,080
1.02.02.01.01	Interest in associated companies	53,496	44,080
1.02.02.01.04	Interest in jointly-controlled subsidiaries	14,764	0
1.02.03	Property, plant and equipment	2,645,714	1,948,170
1.02.03.01	Construction in progress	1,349,217	925,883
1.02.03.02	Right-of-use in lease	1,296,497	1,022,287
1.02.04	Intangible assets	5,744,055	3,159,926
1.02.04.01	Intangible assets	5,744,055	3,159,926
1.02.04.01.02	Intangible assets	5,744,055	3,159,926

Consolidated financial statements / Balance sheet -**Liabilities (In thousands of Reais)**

Code of account	Account description	Current quarter 09/30/2023	Prior year 12/31/2022
2	Total liabilities	11,533,043	7,791,770
2.01	Current liabilities	1,918,079	1,234,135
2.01.01	Social and labor charges	380,761	227,600
2.01.01.02	Labor obligations	380,761	227,600
2.01.02	Suppliers	575,225	364,268
2.01.02.01	Domestic suppliers	574,447	363,971
2.01.02.02	Foreign suppliers	778	297
2.01.03	Tax obligations	84,038	47,922
2.01.03.01	Federal tax obligations	46,009	26,023
2.01.03.01.01	Income tax and social contribution payable	16,031	7,110
2.01.03.01.02	Taxes and contributions payable	29,978	18,913
2.01.03.02	State tax obligations	77	67
2.01.03.03	Municipal tax obligations	37,952	21,832
2.01.04	Loans and financing	707,604	535,820
2.01.04.01	Loans and financing	347,068	12,838
2.01.04.01.01	In domestic currency	9,340	12,838
2.01.04.01.02	In foreign currency	337,728	0
2.01.04.02	Debentures	97,435	348,081
2.01.04.03	Financing through lease	263,101	174,901
2.01.05	Other liabilities	170,451	58,525
2.01.05.02	Other	170,451	58,525
2.01.05.02.01	Dividends and interest on own capital payable	78,725	219
2.01.05.02.04	Accounts payable - acquisition of companies	64,769	40,337
2.01.05.02.06	Other liabilities	26,957	17,969
2.02	Non-current liabilities	4,423,019	3,856,550
2.02.01	Loans and financing	3,369,286	3,142,265
2.02.01.01	Loans and financing	2,612	0
2.02.01.01.01	In domestic currency	2,612	0
2.02.01.02	Debentures	2,199,179	2,198,917
2.02.01.03	Financing through lease	1,167,495	943,348
2.02.02	Other liabilities	388,790	287,609
2.02.02.02	Other	388,790	287,609
2.02.02.02.03	Accounts payable - acquisition of companies	375,171	276,326
2.02.02.02.04	Tax installments	13,619	8,708
2.02.02.02.06	Other liabilities	0	2,575
2.02.03	Deferred taxes	549,898	397,589
2.02.03.01	Deferred income tax and social contribution	549,898	397,589
2.02.04	Provisions	115,045	29,087
2.02.04.01	Tax, social security, labor and civil provision	115,045	29,087
2.02.04.01.01	Tax provisions	92,003	26,640
2.02.04.01.02	Social security and labor provisions	25,774	26,829
2.02.04.01.04	Provisions Civil	32,040	9,738
2.02.04.01.05	Judicial deposits	-34,772	-34,120
2.03	Consolidated shareholders' equity	5,191,945	2,701,085
2.03.01	Realized capital	2,736,029	1,717,222
2.03.02	Capital reserves	1,915,413	603,212

Consolidated financial statements / Balance sheet -

Liabilities (In thousands of Reais)

Code of account	Account description	Current quarter 09/30/2023	Prior year 12/31/2022
2.03.02.04	Options granted	0	38,050
2.03.02.07	Capital reserve	1,915,413	565,162
2.03.04	Profit reserves	201,860	361,102
2.03.04.01	Legal reserve	148,616	148,616
2.03.04.05	Profit retention reserve	24,838	187,291
2.03.04.09	Treasury shares	-9,213	-19,971
2.03.04.10	Investment reserve	37,619	45,166
2.03.05	Retained earnings/losses	249,948	0
2.03.06	Equity valuation adjustments	73,884	0
2.03.09	Non-controlling interest	14,811	19,549

Consolidated financial statements / Statement of

income (In thousands of Reais)

Code of account	Account description	Current quarter 07/01/2023–09/30/2023	Accumulated of the current year 01/01/2023–09/30/2023	Same quarter of the prior year 07/01/2022–09/30/2022	Accumulated of the prior year 01/01/2022–09/30/2022
3.01	Revenue from sales of goods and/or services	1,870,045	4,766,409	1,146,634	3,348,293
3.02	Cost of goods and/or services sold	-1,342,480	-3,427,074	-811,563	-2,388,117
3.03	Gross income (loss)	527,565	1,339,335	335,071	960,176
3.04	Operating expenses/revenues	-209,586	-609,081	-121,340	-353,539
3.04.01	Sales expenses	-42,712	-84,725	0	0
3.04.02	General and administrative expenses	-168,905	-522,591	-121,590	-354,204
3.04.04	Other operating revenues	1,855	-2,196	0	0
3.04.04.02	Other operating revenues (expenses), net	1,855	-2,196	0	0
3.04.06	Equity in net income of subsidiaries	176	431	250	665
3.05	Income (loss) before financial income (loss) and taxes	317,979	730,254	213,731	606,637
3.06	Financial income (loss)	-102,906	-291,955	-99,411	-251,368
3.06.01	Financial revenues	60,852	164,738	28,954	70,626
3.06.02	Financial expenses	-163,758	-456,693	-128,365	-321,994
3.07	Income (loss) before financial income (loss) and taxes	215,073	438,299	114,320	355,269
3.08	Income tax and social contribution	-43,257	-98,617	-26,852	-96,836
3.08.01	Current	-43,896	-121,836	-50,746	-140,817
3.08.02	Deferred	639	23,219	23,894	43,981
3.09	Net income (loss) from continued operations	171,816	339,682	87,468	258,433
3.11	Consolidated income/loss for the period	171,816	339,682	87,468	258,433
3.11.01	Attributed to the Parent Company's shareholders	174,198	342,478	96,006	276,956
3.11.02	Assigned to non-controlling partners	-2,382	-2,796	673	1,478
3.99	Earnings per share - (Reais / Share)				
3.99.01	Basic earnings per share				
3.99.01.01	Common shares	0	0	0.30485	0.87797
3.99.02	Diluted earnings per share				
3.99.02.01	Common shares	0	0	0.30471	0.87756

Consolidated financial statements / Statement of

comprehensive income (In thousands of Reais)

Code of account	Account description	Current quarter 07/01/2023–09/30/2023	Accumulated of the current year 01/01/2023–09/30/2023	Same quarter of the prior year 07/01/2022–09/30/2022	Accumulated of the prior year 01/01/2022–09/30/2022
4.01	Consolidated net income for the period	171,816	339,682	96,679	278,434
4.03	Consolidated comprehensive income for the period	171,816	339,682	96,679	278,434
4.03.01	Attributed to the Parent Company's shareholders	174,198	342,478	96,006	276,956
4.03.02	Assigned to non-controlling partners	-2,382	-2,796	673	1,478

Consolidated financial statements / Statement of cash flows, indirect**method (In thousands of reais)**

Code of account	Account description	Accumulated of the current year 01/01/2023–09/30/2023	Accumulated of the prior year 01/01/2022–09/30/2022
6.01	Net cash from operating activities	1,015,388	711,693
6.01.01	Cash generated in operations	1,439,677	1,089,318
6.01.01.01	Net income for the period	339,682	278,435
6.01.01.02	Income tax and social contribution	98,617	96,836
6.01.01.03	Financial revenues and expenses	384,065	309,888
6.01.01.04	Depreciation and amortization	485,499	331,055
6.01.01.05	Equity in net income of subsidiaries	-431	-664
6.01.01.06	Stock option plan	10,510	9,752
6.01.01.07	Formation (reversal) of provision for tax, labor and civil risks	6,620	4,587
6.01.01.08	Estimated losses from disallowance and default	50,987	36,343
6.01.01.09	Profit sharing	65,724	43,855
6.01.01.10	Other	-1,596	-20,769
6.01.02	Changes in assets and liabilities	-329,305	-218,008
6.01.02.01	(Increase) decrease in accounts receivable	-295,682	-134,290
6.01.02.02	(Increase) decrease in inventories	2,933	-12,863
6.01.02.03	(Increase) decrease in recoverable taxes	6,833	-14,016
6.01.02.04	(Increase) decrease in judicial deposits	2,042	1,485
6.01.02.05	(Increase) decrease in other assets	-10,383	4,927
6.01.02.06	Increase (decrease) in suppliers	-27,687	-52,837
6.01.02.07	Increase (decrease) in salaries and charges payable	5,646	-4,868
6.01.02.08	Increase (decrease) in tax liabilities	988	-730
6.01.02.09	Increase (decrease) in scheduling of tax payments	-8,386	-3,181
6.01.02.10	Increase (decrease) in other liabilities	-5,609	-1,635
6.01.03	Other	-94,984	-159,617
6.01.03.01	Income tax and social contribution paid	-94,984	-159,617
6.02	Net cash from investment activities	149,664	-707,677
6.02.01	Acquisition of property, plant and equipment and intangible assets	-263,938	-285,127
6.02.02	Securities - funding and income	335,427	-57,503
6.02.03	Payments for acquired companies less cash and cash equivalents	-96,159	-362,609
6.02.04	Paid-up capital in subsidiary	176,531	-462
6.02.07	Yield from interest earning bank deposits (classified as cash)	0	3,470
6.02.08	Acquisition of equity interest	0	-12,300
6.02.10	Other	-2,197	6,854
6.03	Net cash from financing activities	-1,168,191	-28,851
6.03.01	Funding of financing and debentures	0	700,000
6.03.02	(Principal) repayment of financing and debentures	-351,458	-170,123
6.03.03	Interest paid on financing and debentures	-266,234	-158,337
6.03.04	Financial commissions and other	-3,214	-2,823
6.03.05	Derivative financial instruments	0	-846
6.03.06	Capital increase	47	1,696
6.03.07	Dividends and/or interest on own capital	-287,104	-229,148
6.03.08	Drawee risk operation	-5,169	-1,741

Consolidated financial statements / Statement of cash flows (Indirect method)

(In thousands of reais)

Code of account	Account description	Accumulated of the current year	Accumulated of the prior year
		01/01/2023–09/30/2023	01/01/2022–09/30/2022
6.05	Increase (decrease) in cash and cash equivalents	-3,139	-24,835
6.05.01	Opening balance of cash and cash equivalents	17,256	33,722
6.05.02	Closing balance of cash and cash equivalents	14,117	8,887

Consolidated financial statements / Statement of changes in shareholders' equity / DMPL - 01/01/2023–

09/30/2023 (In thousands of reais)

Code of account	Account description	Paid-up capital	Capital reserves, options granted and treasury shares	Profit reserves	Retained earnings or losses	Other comprehensive income	Shareholders' equity	Non-controlling interest	Consolidated shareholders' equity
5.01	Opening balances	1,717,222	583,241	381,073	0	0	2,681,536	19,549	2,701,085
5.03	Adjusted opening balances	1,717,222	583,241	381,073	0	0	2,681,536	19,549	2,701,085
5.04	Capital transactions with partners	1,018,807	1,322,959	-170,000	-92,530	73,884	2,153,120	0	2,153,120
5.04.01	Capital increases	170,111	0	-170,000	0	0	111	0	111
5.04.02	Expenditures with issuance of shares	-320	0	0	0	0	-320	0	-320
5.04.03	Recognized options granted	0	114	0	0	0	114	0	114
5.04.05	Treasury shares sold	0	10,758	0	0	0	10,758	0	10,758
5.04.07	Interest on own capital	0	0	0	-92,530	0	-92,530	0	-92,530
5.04.08	Acquisition of Company's interest	849,016	1,312,087	0	0	73,884	2,234,987	0	2,234,987
5.05	Total comprehensive income	0	0	0	342,478	0	342,478	-2,796	339,682
5.05.01	Net income for the period	0	0	0	342,478	0	342,478	-2,796	339,682
5.06	Internal changes in shareholders' equity	0	0	0	0	0	0	-1,942	-1,942
5.06.04	Investment retention	0	0	162,453	0	0	162,453	0	162,453
5.06.05	Retained earnings	0	0	-162,453	0	0	-162,453	0	-162,453
5.06.06	Non-controlling interest	0	0	0	0	0	0	-1,942	-1,942
5.07	Closing balances	2,736,029	1,906,200	211,073	249,948	73,884	5,177,134	14,811	5,191,945

Consolidated financial statements / Statement of changes in shareholders' equity / DMPL - 01/01/2022–

09/30/2022 (In thousands of reais)

Code of account	Account description	Paid-up capital	Capital reserves, options granted and treasury shares	Profit reserves	Retained earnings or losses	Other comprehensive income	Shareholders' equity	Non-controlling interest	Consolidated shareholders' equity
5.01	Opening balances	1,437,253	12,638	395,392	0	0	1,845,283	9,200	1,854,483
5.03	Adjusted opening balances	1,437,253	12,638	395,392	0	0	1,845,283	9,200	1,854,483
5.04	Capital transactions with partners	1,696	5,297	-214,329	0	0	-207,336	0	-207,336
5.04.01	Capital increases	1,696	0	0	0	0	1,696	0	1,696
5.04.03	Recognized options granted	0	432	0	0	0	432	0	432
5.04.05	Treasury shares sold	0	4,865	0	0	0	4,865	0	4,865
5.04.06	Dividends	0	0	-214,329	0	0	-214,329	0	-214,329
5.05	Total comprehensive income	0	0	0	276,956	0	276,956	1,478	278,434
5.05.01	Net income for the period	0	0	0	276,956	0	276,956	1,478	278,434
5.06	Internal changes in shareholders' equity	0	0	0	0	0	0	5,912	5,912
5.06.04	Retained earnings	0	0	-12,830	0	0	-12,830	0	0
5.06.05	Investment retention	0	0	12,830	0	0	12,830	0	0
5.06.06	Non-controlling interest	0	0	0	0	0	0	5,912	5,912
5.07	Closing balances	1,438,949	17,935	181,063	276,956	0	1,914,903	16,590	1,931,493

Consolidated financial statements / Statement of added value**- (In thousands of reais)**

Code of account	Account description	Accumulated of the current year	Accumulated of the prior year
		01/01/2023–09/30/2023	01/01/2022–09/30/2022
7.01	Revenues	5,100,256	3,601,986
7.01.01	Sale of goods, products and services	5,118,053	3,600,969
7.01.02	Other revenues	25,293	34,332
7.01.04	Formation/reversal of allowance for doubtful accounts	-43,090	-33,315
7.02	Inputs acquired from third parties	-2,213,768	-1,450,426
7.02.01	Cost of products, goods and services sold	-1,998,631	-1,349,018
7.02.02	Materials, energy, outsourced services and other	-214,991	-101,408
7.02.03	Loss/recovery of asset values	-146	0
7.03	Gross added value	2,886,488	2,151,560
7.04	Retentions	-485,499	-331,055
7.04.01	Depreciation, amortization and depletion	-485,499	-331,055
7.05	Net added value produced	2,400,989	1,820,505
7.06	Added value received as transfer	170,642	74,304
7.06.01	Equity in net income of subsidiaries	431	664
7.06.02	Financial revenues	170,211	73,640
7.07	Total added value payable	2,571,631	1,894,809
7.08	Distribution of added value	2,571,631	1,894,809
7.08.01	Personnel	1,110,873	796,773
7.08.01.01	Direct remuneration	789,605	555,205
7.08.01.02	Benefits	252,999	197,185
7.08.01.03	F.G.T.S.	68,269	44,383
7.08.02	Taxes, duties and contributions	614,688	455,286
7.08.02.01	Federal	463,268	348,385
7.08.02.03	Municipal	151,420	106,901
7.08.03	Third-party capital remuneration	506,388	364,316
7.08.03.01	Interest	456,693	321,994
7.08.03.02	Rents	9,476	15,832
7.08.03.03	Other	40,219	26,490
7.08.04	Remuneration of own capital	339,682	278,434
7.08.04.01	Interest on own capital	92,530	0
7.08.04.03	Retained earnings / Loss for the period	249,948	276,956
7.08.04.04	Non-controlling interest in retained earnings	-2,796	1,478

**Notes to the
individual and consolidated financial statements as of September 30, 2023.**
In thousands of reais (R\$), unless otherwise indicated.

Contents

1.	Operations	10
2.	Presentation of financial statements	10
3.	Business combination	13
4.	Risk management	16
5.	Cash and cash equivalents	20
6.	Securities.....	20
7.	Accounts receivable.....	21
8.	Inventories	22
9.	Recoverable taxes.....	22
10.	Other assets.....	22
11.	Investments.....	23
12.	Property, plant and equipment and intangible assets	24
13.	Right-of-use	27
14.	Loans and financing	28
15.	Debentures	29
16.	Leases.....	31
17.	Suppliers	32
18.	Labor obligations	32
19.	Tax liabilities	32
20.	Accounts payable – Acquisition of companies.....	33
21.	Other liabilities.....	34
22.	Current and deferred income tax and social contribution.....	34
23.	Provision for tax, labor, civil risks	36
24.	Related parties.....	39
25.	Shareholders' equity	41
26.	Employee benefits	43
27.	Revenue from rendering of services	45
28.	Cost of services rendered	45
29.	General and administrative expenses	46
30.	Commercial expenses	47
31.	Other operating revenues (expenses), net	47
32.	Financial income (loss)	48
33.	Earnings per share.....	49
34.	Information per business segment.....	50
35.	Insurance coverage	51
36.	Subsequent event.....	51

1. Operations

1.1 The Company

Fleury S.A. ("Fleury", "Parent Company" or "Company" and, together with its subsidiaries, "Fleury Group" or "Group") is a publicly-held corporation listed in the Novo Mercado segment of B3 S.A. – Brasil, Bolsa e Balcão, under the ticker "FLRY3", headquartered in the city of São Paulo. The Company is engaged in the provision of medical services in the diagnostic, laboratory support (Lab-to-Lab), treatment, clinical analysis, health management, medical care, orthopedics and ophthalmology areas, toxicological exam and offers its digital healthcare platform.

1.2 New businesses

ABPF Oncologia

On January 10, 2023, Fleury S.A. completed the incorporation of a new company, in partnership with Atlântica Hospitais e Participações S.A. The new company is initially called ABPF Oncologia S.A., and aims at coordinating the care of the cancer patient's journey with preventive solutions, clinical research, and excellent care through an integrated, multichannel, humanized, and patient-centered solution. At the closing of the transaction, Fleury, BP (Beneficência Portuguesa de São Paulo), and Atlântica Hospitais each subscribed and paid in one third of the voting share capital of the new company. Fleury's contribution was R\$ 14 million, and is recognized under the equity accounting method.

Gênese

On June 14, 2023, Fleury S.A. completed the closing of the transaction with Sociedade Beneficente Israelita Brasileira Hospital Albert Einstein to act, through Gênese Análises Genômicas S.A., in the performance of genomic tests, as well as in the development of integrated solutions, research, development of processes and services to directly serve the Personalized and Precision Medicine market in general. Fleury will have a majority interest and control of Gênese, which aims to become a benchmark in the provision of services related to genomics, molecular analysis and genetics. There was no impact on these financial statements, as the start-up date will be January 2024 and there was no contribution from Fleury.

1.3 Tax transparency report

On 9/28/23, we released the 1st Tax Transparency Report (RTF) of Fleury Group; this report marks the beginning and a new phase of the Group's tax area, connecting to ESG issues. The RTF provides the market and society at large with a clear and objective view of our tax governance, as well as the extent to which we positively impact society by paying taxes. It is important to emphasize that this is not yet mandatory in Brazil; Fleury Group is a pioneer in the health sector in promoting such disclosure.

2. Presentation of financial statements

The Fleury Group's individual and consolidated financial statements were approved by the Audit Committee and the Board of Directors at meetings held on October 27 and 31, 2023, respectively.

All relevant information used by Management is presented in these financial statements, as OCPC07.

The individual and consolidated quarterly information is presented in thousands of Reais, which is the functional currency of Fleury Group.

a) Conclusion of business combination - Hermes Pardini

With the conclusion of the business combination as of April 28, 2023 (see Note 3), the financial information of Hermes Pardini and its subsidiaries was prepared using the same accounting practices as Fleury S.A. and started to be consolidated as of May 2023 in the financial statements of Fleury Group, thus, not being comparable with the financial information disclosed as of December 31, 2022 (equity balances) and September 30, 2022 (statement of income, cash flow and statement of added value).

Moreover, on July 19, 2023, CVM and B3 S.A. – Brasil, Bolsa, Balcão (“B3”) granted the requests: (i) to cancel the registration of the Company as an issuer of Instituto Hermes Pardini’s securities, Category “A”, before the CVM, pursuant to Article 55 of CVM Resolution 80, dated March 29, 2022; and (ii) the consequent cancellation of Hermes Pardini’s listing with B3 and the Company’s exit from the trading segment of B3 called “Basic Segment” of PARD3.

Individual and consolidated interim financial information

The Company's individual and consolidated interim financial information for the period ended September 30, 2023 were prepared in accordance with technical pronouncement CPC 21 (R1) (Interim Financial Reporting) and in accordance with the international standard IAS 34 Interim Financial Reporting issued by the International Accounting Standards Board (IASB), and presented in a manner consistent with the standards issued by the Brazilian Securities and Exchange Commission, applicable to the preparation of the Quarterly Information.

a) Significant accounting policies

The accounting practices and policies (which include the principles of measurement, recognition and valuation of assets and liabilities), in addition to the main accounting judgments and sources of uncertainty about estimates adopted in the preparation of this quarterly information, are consistent with those adopted and disclosed in annual financial statements of Fleury S.A. for the year ended December 31, 2022 and, therefore, must be analyzed as a whole.

Any additional information to the policies and practices arising from the acquisition of Hermes Pardini are presented in the applicable Notes to the financial statements for this quarter.

b) Subsidiaries and jointly-controlled subsidiary

The consolidated financial statements include the balances of Fleury S.A., its subsidiaries and special-purpose entities represented by exclusive investment funds. In addition, the balance includes an equity interest in a jointly-controlled company, accounted for under the equity method.

Company’s direct and indirect subsidiaries are as follows:

	Ownership percentage of Fleury S.A.	
	09/30/2023	12/31/2022
Direct subsidiaries:		
Centro de Infusões Pacaembu Ltda. (“CIP”)	100%	100%
Fleury Centro de Procedimentos Médicos Avançados S.A. (“Fleury CPMA”)	100%	100%
Fundo de Investimento Kortex Ventures (“Kortex”)	54%	54%
Instituto Hermes Pardini S.A. (“Hermes Pardini”) (a)	100%	-
Laboratório Marcelo Magalhães S.A.	(b)	100%
Métodos Laboratório, Análises Clínicas e Hematologia Ltda.	100%	100%

Indirect subsidiaries:

Centro Avançado de Oftalmologia S.A.	80%	80%
Clínica de Olhos Dr. Moacir Cunha S.A.	80%	80%
CPC – Centro de Patologia Clínica Ltda.	100%	100%
CSV - Central Sorológica de Vitória Ltda. (a)	99%	-
Diagnóstico por Imagem Sete Lagoas Ltda. (a)	100%	-
Fleury Serviços Ortopédicos S.A.	67%	67%
HSB - Hugo Silviano Brandao Ltda. (a)	100%	-
Instituto 9 de Julho – Serviços Médicos S.A.	80%	80%
IACS - Instituto de Análises Clínicas de Santos S.A. (a)	60%	-
IRN - Instituto de Radiologia de Natal Ltda.	100%	100%
Laboratório Bioclínico Ltda.	100%	100%
Laboratório de Pat. Clínica Dr. Paulo Cordeiro de Azevedo Ltda. (a)	100%	-
Laboratório Padrão S.A. (a)	100%	-
Laboratório Pretti Ltda.	100%	100%
Moscogliato – Serviço de Ultra-Som Ltda. (a)	100%	-
PARDIS - Pardini Distribuidora Ltda. (a)	100%	-
Clínica Oftalmológica São Lucas Ltda. (Retina Clinic)	100%	-
Saha Centro de Infusões Ltda.	100%	100%
Saha Serviços Médicos e Hospitalares Ltda.	100%	100%
Sansão Holding S.A. (a)	100%	-
SantéCorp Corretora de Seguros Ltda.	(c)	100%
SantéCorp Ltda.	100%	100%
Saúde iD Ltda.	100%	100%
Toxicologia Pardini Laboratórios S.A. (a)	100%	-
Vita Clínicas Medicina Especializada Ltda.	100%	100%
Vita Ortopedia Serviços Médicos Especializados Ltda.	(d)	100%

Exclusive Investment Funds:

Bradesco Fundo de Investimento em cotas FI Renda Fixa Crédito Privado Exclusivo Beta	100%	100%
Santander FI Exclusivo Alpha Renda Fixa Crédito Longo Prazo	100%	100%

Jointly-controlled subsidiary:

ABPF Oncologia S.A	33.33%	-
Papaiz Associados Diagnóstico por Imagem S/A Ltda.	(e)	51%

(a) Companies from the business combination with Hermes Pardini.

(b) Merged on June 2, 2023 by Fleury S.A., with net assets of R\$ 40,457 million.

(c) Merged on March 31, 2023 by SantéCorp Ltda.

(d) Merged on March 30, 2023 by Fleury Serviços Ortopédicos S.A.

(e) Sale carried out in February 2023.

Main activities:**Fleury S.A.:** diagnostic imaging, clinical analysis, fertility, infusions, genomics, etc.**Fleury CPMA:** diagnostic imaging in certain hospitals, clinical analysis and Day Clinic;**Grupo IRN:** diagnostic imaging services;**SantéCorp:** health management services;**CPC, Pretti, Bioclínico and Métodos:** clinical analysis laboratory services;

Saúde ID: technology service based on data science and artificial intelligence, including Plataforma de Saúde;
CIP and Saha: hospital and immunobiological drug infusion center;
Clínica de Olhos Dr. Moacir Cunha: ophthalmology service centers;
Vita: medicine service specialized in orthopedics;
Instituto Hermes Pardini: clinical analysis, medical imaging, laboratory support ("Lab-to-Lab");
Pardis: resale of merchandise for application in the processing of clinical analysis;
Toxicologia Pardini: toxicological exam;
AFBP (JV Onco): preventive, integrated solutions, and clinical research in oncology;
Kortex: investment fund to invest in startups engaged in digital health, diagnostic medicine and personalized medicine.

c) Standards and interpretations in force and not in force

The Company did not identify current and non-current standards that could materially impact its Financial Statements.

3. Business combination

a) Hermes Pardini

On April 28, 2023, Fleury S.A. completed the acquisition of 100% of Instituto Hermes Pardini. The company was acquired for the amount of R\$ 2,280,972, paid through (i) R\$ 2,234,988 for replacement of shares at the price of R\$ 14.52 per share, where, for each common share, 1.213542977 common share issued by Fleury S.A. was issued in replacement and (ii) R\$ 45,985 in payments in domestic currency.

i) Brief context of operation

Instituto Hermes Pardini S.A. was a publicly-held corporation listed in the Novo Mercado segment of B3 S.A., located in the city of Belo Horizonte, state of Minas Gerais, engaged in the provision of medical services, laboratory research, clinical analysis and complementary diagnostics and therapeutic services, which include precision medicine and imaging tests.

On September 30, 2022, the Company communicated to its shareholders and the market in general the announcement regarding its corporate reorganization, involving the combination of the businesses and shareholding bases of Fleury and Hermes Pardini, through the Private Instrument of Justification Protocol for the Merger of Shares of Instituto Hermes Pardini by Oxônia SP Participações S.A., followed by the Merger of Oxônia SP Participações S.A. by Fleury ("Protocol and Justification" or "Transaction").

The Companies believe that the combination of the two operations represents an excellent opportunity to create value, which may result in significant gains for their shareholders through: (i) increased competitiveness of the Companies in the environment of transformation of the healthcare and diagnostic medicine sector, with geographic complementarity and national presence, robust capital structure, support from its key shareholders, and adequate organizational structure; and (ii) reinforcement of organic and inorganic growth.

On March 23, 2023, SG Order 376/2023 ("SG Order") was issued, whereby the General Superintendence of the Administrative Council for Economic Defense ("CADE") – Brazil's competition regulator – approved (albeit non-definitively) the Operation without restrictions. A period of 15 calendar days (time limitation applied by law) was awaited for approval to become definitive, which occurred on April 14, 2023, thus fulfilling the suspensive conditions of the Business Combination. The implementation of the operation resulted in:

- (a) Approval of distribution of dividends in the total amount of R\$ 273,224,582.00, representing R\$ 2.154102722 per common share of Hermes Pardini ("Pardini Pre-Approved Dividends"), provided that: the Pardini Pre-Approved Dividends were declared on behalf of the shareholders based on Hermes Pardini's shareholding position at the closing of trading session on the Transaction

Completion Date, at a time prior to the Transaction completion. Pardini Pre-Approved Dividends were paid as of May 30, 2023;

- (b) Approval of redemption value per share (as defined in the Protocol and Justification), paid in local currency in the amount of R\$ 45,985 in a single installment on May 12, 2023, for each one (1) common share issued by Hermes Pardini. The Redemption Value per Share is equivalent to R\$ 0.362537686, where all adjustments provided for in the Protocol and Justification (including due to Pardini Pre-Approved Dividends, within the criteria established in item 3.6 of the Protocol and Justification) were considered and the correction pro rata die by the projected changes in the CDI rate, as of the date of approval of the Transaction by the Extraordinary General Meeting of Hermes Pardini, held on August 18, 2022, until April 28, 2023, in line with the provisions of the Protocol and Justification;
- (c) Approval in the Closing Term, the Final Exchange Ratio per Share is 1.213542977 common share issued by Fleury for each one (1) common share of Hermes Pardini, already considering all the adjustments provided for in the Protocol and Justification, subject to the provisions of the Closing Term.
- (d) Approval of the date April 28, 2023 as the "Transaction Completion Date" was April 28, 2023, under the terms and conditions of item 4.6 of the Protocol and Justification, which was the reference date for defining the Hermes Pardini shareholders who received the common shares issued by Fleury, the Redemption Value per Share and the Pardini Pre-Approved Dividends (as defined above).

ii) Identifiable net assets acquired and goodwill – Hermes Pardini

The estimated allocation of the amount paid/consideration was based on an assessment of the fair value of net assets acquired from Hermes Pardini (IHP) on April 28, 2023 (date of obtaining control).

The fair value of identifiable assets acquired and liabilities assumed in the business combination were estimated using the present value and replacement cost adjustment method. Fair value estimates using the discounted cash flow methodology were based on a discount rate of 12.2% p.a.

Assets and liabilities acquired and recognized on the acquisition date are presented below:

Assets	04/28/2023	Liabilities	04/28/2023
Cash and cash equivalents	224,653	Suppliers	250,011
Securities	15,064	Loans and financing	435,155
Accounts receivable (a)	460,350	Tax liabilities	20,806
Inventory	41,553	Labor obligations	95,425
Recoverable taxes	42,526	Lease	355,904
Other assets	42,823	Tax installments	17,107
Deferred taxes	41,948	Accounts payable – acquisition of companies	197,544
Property, plant and equipment	337,662	Provision for legal risks	16,543
Intangible assets	942,259	Deferred taxes	99,388
Right-of-use	326,098	Other liabilities	280,541
		Liabilities	1,768,424
		Shareholders' equity	706,512
Total assets	2,474,936	Total liabilities and shareholders' equity	2,474,936

- (a) The balance of accounts receivable is net of estimated losses on disallowances and default in the amount of R\$ 17,886.

iii) Estimate for allocation of transferred consideration price (preliminary):

Issue of shares (number)	153,924,773
Value per share (04/28/2023)	14.52
Amount paid for share replacement	2,234,988
Redemption of common shares – paid in cash	45,984
Fair value of the transaction	2,280,972
Shareholders' equity	706,512
Gain (loss) in property, plant and equipment, net	117,141
Client portfolio – Lab-to-Lab	349,219
Surplus of intangible assets – Brands	422,944
Provision for risks – Possible	(67,416)
Deferred tax	(135,641)
Shareholders' equity – fair value	1,392,759
Goodwill on business combination (goodwill)	888,213

With the conclusion of the business combination of the Hermes Pardini Group on April 28, 2023, the financial information started to be consolidated in the Fleury Group's financial statements as of the base date of May 2023.

The Company opted not to present pro-forma financial statements; thus, the financial information for this quarter is not comparable with the financial information for December 31, 2022 (equity balances) and September 30, 2022 (statements of income, cash flow, and added value).

b) Retina Clinic

On April 04, 2023, Fleury S.A., through its direct subsidiary, Fleury Centro de Procedimentos Médicos Avançados S.A (CPMA) completed the acquisition of 100% of Retina Clinic's shares. The company was acquired for the amount of R\$ 22,523, of which R\$ 14,893 was paid in cash, less R\$ 434 referring to price adjustments, and R\$ 6,500 retained for indemnity and earnout of R\$ 713.

i) Identifiable net assets acquired and goodwill – Retina Clinic (preliminary)

The estimated allocation of the amount paid/consideration was based on an assessment of the fair value of net assets acquired from Retina Clinic on March 31, 2023 (control acquisition date).

The fair value of identifiable assets acquired and liabilities assumed in the business combination were estimated using the present value and replacement cost adjustment method. Fair value estimates using the discounted cash flow methodology were based on a discount rate of 13.6% p.a.

Assets and liabilities acquired and recognized on the acquisition date are presented below:

Assets	03/31/2023	Liabilities	03/31/2023
Cash and cash equivalents	1,234	Suppliers	1,141
Accounts receivable (a)	1,201	Loans and financing	160
Recoverable taxes	13	Tax liabilities	630
Judicial deposits	1,530	Labor obligations	361
Other assets	8	Lease	6,305
Investments	137	Other liabilities	39
Property, plant and equipment / Intangible assets	5,971	Liabilities	8,636
Right-of-use	6,161	Shareholders' equity	7,619
Total assets	16,255	Total liabilities and shareholders' equity	16,255

(a) The balance of accounts receivable is net of losses on disallowances and default in the amount of R\$ 448.

ii) Estimate for allocation of transferred consideration price:

Purchase price	22,523
(-) Adjustment to present value	(790)
Adjusted acquisition price	21,733
Shareholders' equity	7,619
Gain (loss) in property, plant and equipment, net	2,796
Client portfolio	1,100
Surplus of Intangible assets - Brand	4,040
Deferred taxes	(1,325)
Shareholders' equity – fair value	14,230
Goodwill on business combination (goodwill)	7,503

c) Methodology used to determine the fair values of business combinations

Property, plant and equipment: The fair value of these assets was determined based on the method of quantifying the cost in obtaining the value of a new, identical or similar machine and/or equipment, through market research with manufacturers, suppliers and/or representatives, plus, when applicable, assembly and transportation expenses.

Client portfolio/Contracts: The fair value of intangible assets arising from client relationships was calculated considering the Multi Period Earning Excess Method (MPEEM) method, which uses the Churn Rates as an approach.

Legal risks: The fair value of contingent liabilities was calculated based on estimates made by legal advisors.

Brands: the related fair value considered the Royalty Relief method, estimated the value of these types of intangible assets, capitalizing the royalties that are saved since the company owns the intangible assets.

Impact of the 2023 acquisitions on the Fleury Group's results

The amounts of net revenue and income (loss) for the period before the acquirees' business combination, attributable to additional businesses generated as of the acquisition date and that were included in the consolidated statement of income for the period from this financial information include:

	Hermes Pardini	Retina Clinic
Net Revenue	967,416	12,200
Net income for the period	81,350	(1,525)

If the companies Hermes Pardini and Retina Clinic had been consolidated starting January 01, 2023, the consolidated statement of income would show pro-forma net revenue of R\$ 4,219,526 and pro-forma profit of R\$ 269,070. This information was obtained by simply aggregating the amounts of the acquirees and acquirer; it does not present the actual consolidated amounts for the year, and therefore is not audited.

Additionally, the costs related to these transactions were recorded in general and administrative expenses (see Note 29).

4. Risk management

The main risk factors to which the Company and its subsidiaries are exposed are financial and operating risks, including market, foreign exchange, interest rate, credit and liquidity risk. These risks, which are inherent to their activities, are managed through internal policies and controls supervised and monitored through monthly management reports.

Fair value hierarchy

The assumptions used by the Company to determine the hierarchy and disclose the fair values of financial instruments are as follows:

- Level 1: quoted price in active markets for identical assets or liabilities;
- Level 2: other techniques for which all data that has significant effect on the recorded fair value is observable, either directly or indirectly.
- Level 3: techniques that use data that have significant effect on the recorded fair value, and that are not based on data observable in the market.

a) Accounting classification and fair values

Financial assets	Level 1	Level 2
Cash and cash equivalents	14,117	-
Securities	-	1,084,195
Accounts receivable	1,561,396	-
Financial liabilities		
Suppliers	(575,225)	-
Lease	(1,430,596)	-
Financing and debentures, except drawee risk	(3,490)	(300,405)
Derivative financial instruments, net	-	(37,323)
Drawee risk	(8,462)	-
Debentures	-	(2,296,614)
Tax installments	(24,631)	-
Interest on own capital and dividends payable	(78,725)	-
Accounts payable - Acquisition of companies	(370,265)	(69,675)
Balances at September 30, 2023	(915,881)	(1,619,822)
December 31, 2022	(953,522)	(1,133,123)

Due to the nature of balances, it is assumed that the fair value of the Company's financial instrument balances is close to their book value. The comparison between the calculated values and fair values did not present material differences.

b) Capital management

Fleury Group monitors capital based on the consolidated leverage ratio, as shown below:

	09/30/2023	12/31/2022
Loans and debentures, except drawee risk	2,637,832	2,547,762
Accounts payable from acquisitions	439,940	299,542
Drawee risk	8,462	12,074
Cash and cash equivalents	(14,117)	(17,256)
Securities	(1,084,195)	(1,413,875)
Net debt	1,988,044	1,428,247
EBITDA/LAJIDA LTM* (Earnings before interest, taxes, depreciation and amortization)	1,709,910	1,189,707
Leverage ratio (Net debt / EBITDA LTM*)	1.16	1.20

(*) LTM (last twelve months)

c) Financial and market risks

Interest rate risk

The Company has financing in local currency subject to interest rates pegged to indexes, such as the CDI, as well as the balance of taxes payable in installments, which bears interest indexed to the SELIC rate and accounts payable from acquisitions by means of the IPCA. The risk inherent in these liabilities arises from the possibility of fluctuations in these rates impacts its cash flows.

Credit risk

The Fleury Group is exposed to credit risk in its operating activities reflected in the balance sheet in the group of accounts receivable (see Note 7).

The Company and its subsidiaries are also subject to credit risks related to operations maintained in financial institutions represented by bank deposits, interest earning bank deposits and derivative instruments. The Management considers the risk low, since operations are carried out in prime banks and there are treasury policies with specific limits for allocation of funds.

Liquidity risk

Cash flow forecasting is carried out by the Finance Department, which monitors rolling forecasts of the Fleury Group's liquidity requirements to ensure it has sufficient cash to meet operational needs. It also always maintains sufficient headroom on its undrawn committed borrowing facilities so that the Group does not breach borrowing limits or covenants (where applicable) of any of its financing and debentures. This forecast takes into consideration the Group's financing plans, compliance with covenants, attainment of the internal goals of the balance sheet quotient and, if applicable, external or legal regulatory requirements - for example, currency restrictions.

Surplus cash held by the operating entities, in addition to the balance required for managing working capital, is allocated to investments with appropriate maturities or sufficient liquidity to provide the necessary margin as determined by the forecasts.

The chart below analyzes Fleury Group's liabilities and financial instruments, by maturity brackets, corresponding to the remaining period in the balance sheet up to the contractual date of maturity. The amounts disclosed are contracted (consolidated) undiscounted cash flows, and, therefore, they cannot be reconciled with book values.

September 30, 2023	Book value	Amount contracted	≤1 year	01-02 years	02-05 years	>05 years
Debentures	2,296,614	3,355,895	304,052	740,022	1,913,927	397,894
Lease	1,430,596	2,004,765	360,313	344,370	704,203	595,879
Suppliers	575,225	575,525	575,525	-	-	-
Loans and financing	304,017	310,102	306,982	953	2,167	-
Accounts payable - acquisition of companies	439,940	439,940	64,769	375,171	-	-
Other liabilities	26,781	26,781	26,778	3	-	-
Drawee risk	8,462	8,462	8,462	-	-	-
Derivative financial instruments	37,377	37,377	37,377	-	-	-
	5,119,012	6,758,847	1,684,258	1,460,519	2,620,297	993,773

Foreign exchange risk

The Fleury Group uses derivatives to hedge its exposures to foreign currency. Derivatives are recognized at fair value on their execution date and remeasured on a monthly basis.

The purpose of the operation is to protect assets. The effects on income (loss) are recognized in "Financial revenues and/or expenses", with a contra entry to "Financial instruments - liabilities" for the balance of the differential payable and in "Financial instruments - assets" for the balance of differential receivable.

The main contractual conditions are as follows:

Type of operation	Contracting	Assets/Liabilities	Maturity	Amount in US\$	Long position	Short position	Mark-to-market
Swap	Nov 2022	USD 7.09% / CDI 1.35%	Nov 2023	56,175	300,405	337,728	37,323

The Company has derivatives on suppliers in foreign currency; the balance sheet on September 30, 2023 is R\$ 9,137 million, the net derivative of this operation on the balance sheet date is R\$ 122 thousand.

d) Operating and Environmental Risk Management

The operating and environmental risk management governance policies are consistent with those adopted and disclosed in the annual financial statements of Fleury S.A. for the year ended December 31, 2022.

e) Statement of sensitivity analysis

Sensitivity analysis for interest rate changes

To calculate the probable scenario, the projections disclosed by the Market Focus Report published by the Central Bank of Brazil on September 30, 2023 were used. The "Possible" and "Remote" scenarios consider a decrease in this rate of 0.25% p.a. The results in nominal terms were as follows:

	Book balance	Probable	Possible	Remote
	CDI (p.a.)	12.50%	12.25%	12.00%
Interest earning bank deposits - Securities	1,084,195	137,151	131,730	126,309
Cash and cash equivalents	12	2	1	1
Working capital	(337,728)	(42,723)	(41,034)	(39,345)
Debentures	(2,296,614)	(290,522)	(279,039)	(267,556)
Net exposure in CDI	(1,550,135)	(196,092)	(188,342)	(180,591)

5. Cash and cash equivalents

	Parent Company		Consolidated	
	09/30/2023	12/31/2022	09/30/2023	12/31/2022
Cash and banks	2,949	9,121	14,105	17,256
Investments with daily liquidity	-	-	12	-
Total	2,949	9,121	14,117	17,256

6. Securities

	Parent Company		Consolidated	
	09/30/2023	12/31/2022	09/30/2023	12/31/2022
Fund quotas – Pegged to the DI rate	641,729	1,174,965	1,064,989	1,393,440
Bank Deposit Certificates (CDB)	18,898	17,664	18,898	17,664
Kortex Venture Capital – Fixed income funds	15,091	14,809	308	2,771
Total	675,718	1,207,438	1,084,195	1,413,875
Current	641,731	1,174,965	962,521	1,292,234
Non-current	33,987	32,473	121,674	121,641

a) Changes in the interest earning bank deposits balance (securities + investments with daily liquidity)

	Parent Company		Consolidated	
	09/30/2023	09/30/2022	09/30/2023	09/30/2022
Opening balance	1,207,438	737,395	1,413,875	833,722
Investment	1,477,713	2,088,607	2,777,343	2,382,705
Business combination (a)	-	-	15,064	12,103
Earnings	82,731	55,971	113,555	67,023
Redemption	(2,092,164)	(2,204,217)	(3,235,642)	(2,410,345)
Total	675,718	677,756	1,084,195	885,208

(a) Additional information, see Note 3.

7. Accounts receivable

a) Breakdown of the balance

	Parent Company		Consolidated	
	09/30/2023	12/31/2022	09/30/2023	12/31/2022
Amounts billed	657,345	574,963	1,053,393	645,525
Amounts to be billed	216,404	139,501	543,593	225,890
	873,749	714,464	1,596,986	871,415
Estimated losses from disallowances and default	(15,512)	(12,915)	(35,590)	(14,566)
Total	858,237	701,549	1,561,396	856,849
Current	858,237	701,549	1,558,622	856,849
Non-current	-	-	2,774	-

b) Aging analysis

	Parent Company		Consolidated	
	09/30/2023	12/31/2022	09/30/2023	12/31/2022
Undue	766,320	641,993	1,386,225	785,354
Overdue				
≤120	71,754	49,435	147,727	58,482
121–360	34,556	20,232	53,711	24,094
>361	1,119	2,804	9,323	3,485
Total	873,749	714,464	1,596,986	871,415

c) Changes in estimated losses from disallowances and default

	Parent Company		Consolidated	
	09/30/2023	09/30/2022	09/30/2023	09/30/2022
Balance at the beginning of the period	(12,915)	(13,613)	(14,566)	(15,250)
Additions of disallowances and default (Notes 27 and 31)	(31,888)	(30,811)	(43,090)	(34,020)
Business combination (a)	-	-	(17,887)	-
Write-off of non-collectible securities	29,291	30,193	39,953	32,598
Balance at the end of the period	(15,512)	(14,231)	(35,590)	(16,672)

(a) Additional information, see Note 3.

8. Inventories

a) Breakdown of the balance

	Parent Company		Consolidated	
	09/30/2023	12/31/2022	09/30/2023	12/31/2022
Diagnostic kits	32,735	36,147	70,292	36,207
Auxiliary laboratory materials	11,253	11,698	19,496	12,008
Nursing and sample collection materials	14,395	14,799	18,939	21,090
Auxiliary laboratory materials (Infusion)	1,366	1,591	15,647	19,807
Administrative, promotional and other materials	3,926	4,759	7,180	5,814
Goods for resale	-	-	2,233	-
Auxiliary laboratory materials (Ophthalmology)	-	-	1,409	1,650
Total	63,675	68,994	135,196	96,576

9. Recoverable taxes

	Parent Company		Consolidated	
	09/30/2023	12/31/2022	09/30/2023	12/31/2022
ISS	9,226	9,164	10,068	9,705
INSS	1,378	3,255	2,699	3,935
VAT (ICMS) (a)	-	-	2,266	-
PIS AND COFINS	378	378	1,956	1,117
Total	10,982	12,797	16,989	14,757

(a) Refers to ICMS on resale of the subsidiary Pardis

10. Other assets

	Parent Company		Consolidated	
	09/30/2023	12/31/2022	09/30/2023	12/31/2022
Employee credits/payroll	28,199	19,111	38,214	20,036
Financial asset - Call option Vita (a)	-	-	27,280	27,759
Costs with obtaining contracts (b)	19,248	8,050	19,248	8,069
Prepaid expenses (c)	6,019	3,495	12,099	3,960
Advances to suppliers	46	119	10,728	5,604
Rental advances	4,362	7,939	4,362	7,939
Prepaid Municipal property tax	31	85	1,088	85
Other	1,409	6,517	3,005	16,812
Total	59,314	45,316	116,024	90,264
Current	30,051	29,378	59,173	36,499
Non-current	29,263	15,938	56,851	53,765

(a) Pursuant to the purchase and sale agreement entered into by Fleury CPMA and physicians, CPMA has the option (right) to acquire the non-controlling interest that represents 33.33% in the period of 3 years from the acquisition to be completed in June 2024.

(b) These balances refer to: Partnership agreement with hospitals to obtain a contract to provide clinical analysis services, amounts are amortized over the contractual term.

(c) This balance mainly consists of expenses with renewal of licenses, insurance and guarantees.

11. Investments

	Parent Company		Consolidated	
	09/30/2023	12/31/2022	09/30/2023	12/31/2022
Direct/indirect subsidiary	4,013,839	1,613,628	8,770	3,597
Investees of the Kortex Fund	-	-	28,266	20,096
ABF Oncologia (JV)	14,764	-	14,764	-
Prontmed	12,000	12,000	12,000	12,000
Other interests	4,459	8,386	4,460	8,387
Total	4,045,062	1,634,014	68,260	44,080

Significant information about parent company's investments

Direct subsidiaries	Base Date	Interest in paid-up capital - %	Capital quotas (qty)	Shareholders' equity	Income (loss) for the period
Fleury CPMA	09/30/2023	100%	1,021,594	951,969	(12,509)
	12/31/2022	100%	989,194	932,078	(6,143)
Hermes Pardini Group	09/30/2023	100%	866,065	1,066,716	81,350
	12/31/2022	-	-	-	-
CIP group (including Saha)	09/30/2023	100%	79,611	147,125	30,630
	12/31/2022	100%	73,111	109,995	20,259
Métodos	09/30/2023	100%	2,336	6,619	3,828
	12/31/2022	100%	2,336	2,895	680

Changes in balances of investments

Change - Parent company:

Investor	Investees	Balance at 12/31/2022	Business combination	Paid-up capital	Equity in net income of subsidiaries	Fair value	Merger	Other changes	Balance at 09/30/2023
Fleury S.A.	Pardini	-	2,416,613	281,200	81,350	(22,535)	-	-	2,756,628
Fleury S.A.	Fleury CPMA	933,444	-	32,400	(12,509)	-	-	-	953,335
Fleury S.A.	Diagmax	3,512	-	-	-	-	-	(3,512)	-
Fleury S.A.	Inlab	1,912	-	-	-	-	-	(1,912)	-
Fleury S.A.	CIP	235,208	-	6,500	30,630	(96)	-	-	272,242
Fleury S.A.	Marcelo Magalhães	411,108	-	-	10,420	(175)	(421,448)	94	1.00
Fleury S.A.	Métodos	28,444	-	-	3,828	(637)	-	-	31,635
Fleury S.A.	ABF (JV Oncologia)	-	-	14,333	431	-	-	-	14,764
Fleury S.A.	Prontmed	12,000	-	-	-	-	-	-	12,000
Fleury S.A.	Other	8,386	-	-	-	-	-	(3,927)	4,459
Total - Parent Company		1,634,014	2,416,613	334,433	114,150	(23,443)	(421,448)	(9,257)	4,045,062

Changes - Consolidated:

Investor	Investees	Balance at 12/31/2022	Acquisition	Paid-up capital	Equity in net income of subsidiaries	Other changes	Balance at 09/30/2023
Fleury S.A.	ABF (JV Oncologia)	-	-	14,333	431	-	14,764
Fleury S.A.	Prontmed	12,000	-	-	-	-	12,000
Fleury S.A.	Other	8,387	-	-	-	(3,927)	4,460
Kortex	Other	20,096	-	-	-	(411)	19,685
Kortex	Siphox	-	5,020	-	-	-	5,020
Kortex	Webe Care	-	3,738	-	-	(177)	3,561
Fleury CPMA	Other	3,597	-	-	-	5,173	8,770
Total consolidated		44,080	8,758	14,333	431	658	68,260

12. Property, plant and equipment and intangible assets

a) Breakdown of balance of property, plant and equipment

Parent Company					
	Average annual depreciation rate (%)	Cost	Accumulated depreciation	Net balance at 09/30/2023	Net balance at 12/31/2022
Machinery and equipment	10	882,880	(479,705)	403,175	382,551
Leasehold improvements	20	604,543	(376,243)	228,300	144,712
Facilities	10	340,856	(274,026)	66,830	53,257
Property, plant and equipment in progress	-	38,600	-	38,600	176,380
IT equipment	20	121,272	(93,933)	27,339	30,258
Real estate	2	27,761	(7,658)	20,103	20,645
Furniture and fixtures	10	55,164	(40,708)	14,456	11,877
Land	-	13,637	-	13,637	13,637
Vehicles	20	729	(638)	91	62
Total		2,085,442	(1,272,911)	812,531	833,379

Consolidated					
	Average annual depreciation rate (%)	Cost	Accumulated depreciation	Net balance at 09/30/2023	Net balance at 12/31/2022
Machinery and equipment	10	1,528,644	(801,476)	727,168	428,723
Leasehold improvements	20	856,535	(473,712)	382,823	170,578
Facilities	10	392,679	(317,244)	75,435	58,838
IT equipment	20	194,459	(147,810)	46,649	35,355
Property, plant and equipment in progress	-	39,833	-	39,833	177,790
Furniture and fixtures	10	112,253	(69,536)	42,717	19,472
Real estate	2	27,761	(7,659)	20,102	20,645
Land	-	13,637	-	13,637	13,637
Vehicles	20	3,873	(3,020)	853	845
Total		3,169,674	(1,820,457)	1,349,217	925,883

b) Changes in property, plant and equipment

Parent Company							
	Balance at 12/31/2022	Additions	Net write- offs	Depreciation	Merger (a)	Reclass./ Transf.	Balance at 09/30/2023
Machinery and equipment	382,551	23,133	(1,498)	(45,397)	847	43,539	403,175
Leasehold improvements	144,712	18,168	(89)	(50,785)	1,129	115,165	228,300
Facilities	53,257	8,160	(565)	(14,613)	446	20,145	66,830
Construction in progress	176,380	43,859	(250)	-	-	(181,389)	38,600
IT equipment	30,258	3,931	-	(7,791)	436	505	27,339
Real estate	20,645	-	(193)	(349)	-	-	20,103
Furniture and fixtures	11,877	188	(141)	(1,788)	102	4,218	14,456
Land	13,637	-	-	-	-	-	13,637
Vehicles	62	-	-	29	-	-	91
Total	833,379	97,439	(2,736)	(120,694)	2,960	2,183	812,531

(a) Refers to the merger of Inlab, Diagmax and Cedire.

Consolidated								
	Balance at 12/31/2022	Business combination	Additions	Net write- offs	Depreciation	Surplus and loss	Reclass./ Transf.	Balance at 09/30/2023
Machinery and equipment	428,723	187,047	44,186	(1,734)	(75,083)	99,811	44,218	727,168
Leasehold improvements	170,578	130,454	26,246	(123)	(59,823)	(263)	115,754	382,823
Facilities	58,838	2,504	8,288	(650)	(15,384)	1,613	20,226	75,435
IT equipment	35,355	8,401	7,223	(412)	(10,991)	6,560	513	46,649
Construction in progress	177,790	447	45,094	(258)	-	-	(183,240)	39,833
Furniture and fixtures	19,472	14,394	1,744	(377)	(4,132)	7,375	4,241	42,717
Real estate	20,645	-	-	(194)	(349)	-	-	20,102
Land	13,637	-	-	-	-	-	-	13,637
Vehicles	845	386	-	-	(454)	76	-	853
Total	925,883	343,633	132,781	(3,748)	(166,216)	115,172	1,712	1,349,217

c) Breakdown of balance of intangible assets

Parent Company					
	Average annual amortization rate (%)	Cost	Accumulated amortization	Net balance at 09/30/2023	Net balance at 12/31/2022
Goodwill - Future profitability	-	1,816,341	(44,413)	1,771,928	1,467,728
Licenses and software	20	707,706	(548,944)	158,762	181,891
Constructions in progress	-	129,823	-	129,823	89,255
Trademarks and patents	7	91,018	(10,634)	80,384	3,390
Internally developed products	-	6,690	-	6,690	6,690
Total		2,751,578	(603,991)	2,147,587	1,748,954

Consolidated

	Average annual amortization rate (%)	Cost	Accumulated amortization	Net balance at 09/30/2023	Net balance at 12/31/2022
Goodwill - Future profitability	-	4,215,700	(45,212)	4,170,488	2,566,748
Trademarks and patents	7	751,531	(19,264)	732,267	247,544
Licenses and software	20	920,287	(620,136)	300,151	241,922
Constructions in progress	-	144,950	-	144,950	96,087
Internally developed products	-	11,028	(1,092)	9,936	6,690
Client contracts	10	538,529	(189,094)	349,435	735
Commercial points	-	42,743	(6,055)	36,688	-
Non-competition agreement	7	1,326	(1,186)	140	200
Total		6,626,094	(882,039)	5,744,055	3,159,926

d) Changes in intangible assets**Parent Company**

	Balance at 12/31/2022	Additions	Write-offs	Amortization	Merger (a)	Transfers	Balance at 09/30/2023
Goodwill - Future profitability	1,467,728	-	-	-	304,200	-	1,771,928
Licenses and software	181,891	47,814	(436)	(92,473)	-	21,966	158,762
Constructions in progress	89,255	64,403	(35)	-	349	(24,149)	129,823
Trademarks and patents	3,390	-	-	(252)	77,246	-	80,384
Internally developed products	6,690	-	-	-	-	-	6,690
Total	1,748,954	112,217	(471)	(92,725)	381,795	(2,183)	2,147,587

(a) Refers to the merger of Inlab, Diagmax and Cedire.

Consolidated

	Balance at 12/31/2022	Fair value in the acquisition of subsidiaries (a)	Business Combination (b)	Additions	Write-offs	Amortization	Reclass. /Trans.	Surplus/loss	Balance at 09/30/2023
Goodwill - Future profitability	2,566,748	895,716	708,024	-	-	-	-	-	4,170,488
Trademarks and patents	247,544	426,984	69,770	-	-	(1,650)	-	(10,381)	732,267
Licenses and software	241,922	-	75,879	53,562	(401)	(114,792)	43,981	-	300,151
Constructions in progress	96,087	-	18,829	77,327	(59)	-	(47,234)	-	144,950
Internally developed products	6,690	-	2,046	11	-	(351)	1,540	-	9,936
Client contracts	735	350,319	14,244	-	-	(15,770)	-	(93)	349,435
Commercial points	-	-	38,470	-	-	(1,782)	-	-	36,688
Non-competition agreement	200	-	-	-	-	-	-	(60)	140
Total	3,159,926	1,673,019	927,262	130,900	(460)	(134,345)	(1,713)	(10,534)	5,744,055

(a) Refers to the allocation of fair value in the acquisition of Hermes Pardini and Retina.

(b) Refers to net assets of the companies Hermes Pardini and Retina (pursuant to Note 3) and remeasurement of net assets from the acquisition of Saha and Methodos (R\$ 411).

13. Right-of-use

a) Breakdown

Parent Company					
	Average annual depreciation rate (%)	Cost	Accumulated amortization	Net balance at 09/30/2023	Net balance at 12/31/2022
Real estate	13	1,267,117	(496,062)	771,055	808,832
Machinery and equipment	20	178,790	(75,040)	103,750	83,800
IT equipment	25	38,938	(24,946)	13,992	19,048
Vehicles	50	19,255	(13,143)	6,112	7,823
Total		1,504,100	(609,191)	894,909	919,503

Consolidated					
	Average annual depreciation rate (%)	Cost	Accumulated amortization	Net balance at 09/30/2023	Net balance at 12/31/2022
Real estate	13	1,764,278	(707,923)	1,056,355	908,678
Machinery and equipment	20	339,527	(149,063)	190,464	86,683
IT equipment	25	57,031	(29,238)	27,793	19,103
Vehicles	50	46,044	(24,159)	21,885	7,823
Total		2,206,880	(910,383)	1,296,497	1,022,287

b) Changes in right-of-use assets

Parent Company							
	Balance at 12/31/2022	Additions	Renegotiations	Amortization	Write-offs	Merger (a)	Balance at 09/30/2023
Real estate	808,832	53,153	13,322	(93,473)	(32,787)	22,008	771,055
Machinery and equipment	83,800	43,777	1,369	(25,196)	-	-	103,750
IT equipment	19,048	2,070	41	(6,310)	(857)	-	13,992
Vehicles	7,823	1,942	314	(3,615)	(352)	-	6,112
Total	919,503	100,942	15,046	(128,594)	(33,996)	22,008	894,909

(a) Refers to the merger of Inlab, Diagmax and Cedire.

Consolidated

	Balance at 12/31/2022	Business combination (a)	Additions	Renegotiations	Amortization	Write- offs	Balance at 09/30/2023
Real estate	908,678	221,724	63,405	33,236	(133,907)	(36,781)	1,056,355
Machinery and equipment	86,683	83,568	49,610	8,443	(37,135)	(705)	190,464
IT equipment	19,103	14,203	2,453	699	(7,808)	(857)	27,793
Vehicles	7,823	17,302	2,578	803	(6,088)	(533)	21,885
Total	1,022,287	336,797	118,046	43,181	(184,938)	(38,876)	1,296,497

(a) Refers to the acquisition of Hermes Pardini and Retina (pursuant to Note 3) and remeasurement of net assets from the acquisition of Methodos.

14. Loans and financing

Funding – Consolidated

Type	Fixed-rate charges	Signature date	Amount contracted	Final maturity
BNDES FINAME	3.55% p.a.	01/31/2013	4,876	11/15/2023
Bank Credit Bill (CCB)	9.34% p.a.	07/05/2019	1,672	10/11/2023
FINEP	5.00% p.a.	10/31/2018	5,600	02/15/2028
Working capital	USD + 5.47%	06/15/2022	100,000	07/15/2023
Working capital	USD + 7.09%	12/01/2022	300,000	11/27/2023

Information about Hermes Pardini Controlled Working Capital

In July 2022, Pardini took out a loan from Santander (Brasil) S/A, denominated in US dollars, in the original amount of US\$ 18,788, equivalent to R\$ 100,000 on the transaction date, plus interest of 5.47% per annum. A swap operation was contracted on this loan (see Note 4), changing the currency to reais and fixing the interest rate at CDI+1.64% per annum. It was settled in July 2023.

In December 2022, Pardini obtained another loan from Santander (Brasil) S/A, denominated in US dollars, in the original amount of US\$ 56,174, equivalent to R\$ 300,000 on the transaction date, plus interest of 7.09% per annum. A swap operation was contracted on this loan (see Note 4), changing the currency to reais and fixing the interest rate at CDI+1.35% per annum maturing in December 2023.

changes in balances:

Changes – Parent Company	Balance at 12/31/2022	Other operations (a)	Balance at 09/30/2023
Drawee risk	12,051	(5,171)	6,880

Changes - Consolidated	Balance at 12/31/2022	Business combination (Note 3)	Swap	Exchange-rate change	Interest incurred	Interest paid	Amortization of principal	Other operations (a)	Balance at 09/30/2023
Drawee risk	12,074	-	-	-	-	-	-	(3,612)	8,462
BNDES FINAME	465	-	-	-	7	(7)	(387)	-	78
Bank Credit Bill (CCB)	299	-	-	-	79	-	(358)	2	22
FINEP	-	3,694	-	-	103	(90)	(317)	-	3,390
Working capital	-	431,461	10,525	(16,523)	9,319	(5,037)	(92,017)	-	337,728
Total	12,838	435,155	10,525	(16,523)	9,508	(5,134)	(93,079)	(3,610)	349,680
Current	12,838								347,068
Non-current	-								2,612

(a) Refers to changes during the period, considering settlements/write-offs and new hires.

Certain financings contain financial covenants, such as: the implementation or formalization of collateral or fidejussory guarantees, restrictions on the change, transfer or assignment of corporate or shareholding, incorporation, merger or spin-off without the prior consent of the creditor, and the maintenance of financial and liquidity ratios measured every six months.

As of September 30, 2023, the Company and its subsidiaries followed these financial ratios, as well as with the other covenants.

15. Debentures

a) Breakdown – Parent Company

	Issue amount (R\$)	Quantity	Final maturity	Semi-annual interest	Total issued
4 th issue – 2 nd series	10,000	25,000	Apr 2023	CDI + 0.60% p.a.	250,000
5 th issue – 1 st series	1,000	200,000	Dec 2024	CDI + 0.90% p.a.	200,000
5 th issue – 2 nd series	1,000	300,000	Dec 2027	CDI + 1.20% p.a.	300,000
6 th issue – 1 st series	1,000	250,000	July 2025	CDI + 1.35% p.a.	250,000
6 th issue – 2 nd series	1,000	375,000	July 2026	CDI + 1.50% p.a.	375,000
6 th issue – 3 rd series	1,000	375,000	July 2028	CDI + 1.75% p.a.	375,000
7 th issue – 1 st series	1,000	350,000	Apr 2027	CDI + 1.35% p.a.	350,000
7 th issue – 2 nd series	1,000	350,000	Apr-2029	CDI + 1.55% p.a.	350,000

The Company used the amounts raised from the debentures issued to strengthen working capital, maintain its cash strategy, extend its debt profile, and fund investments and acquisitions in the coming years. The debentures issued are unsecured and not convertible into shares.

Changes in debentures

Domestic currency - R\$	12/31/2022	Interest incurred	Interest paid	Amortization of principal	Other operations	09/30/2023
4 th issue – 2 nd series	255,915	11,116	(17,031)	(250,000)	-	-
5 th issue – 1 st series	201,090	20,886	(13,938)	-	-	208,038
5 th issue – 2 nd series	301,670	32,034	(21,376)	-	-	312,328
6 th issue – 1 st series	267,469	26,971	(36,380)	-	-	258,060
6 th issue – 2 nd series	401,489	40,895	(55,163)	-	-	387,221
6 th issue – 3 rd series	401,964	41,627	(56,150)	-	-	387,441
7 th issue – 1 st series	359,351	38,048	(25,213)	-	-	372,186
7 th issue – 2 nd series	359,483	38,605	(25,578)	-	-	372,510
Commissions (5 th , 6 th and 7 th issue)	(1,433)	-	-	-	263	(1,170)
Total	2,546,998	250,182	(250,829)	(250,000)	263	2,296,614
Current	348,081					97,435
Non-current	2,198,917					2,199,179

The maturity dates of Non-current liabilities as of September 30, 2023 (except for commission) are as follows:

Maturity	5 th Issue – 1 st series	5 th Issue – 2 nd series	6 th Issue – 1 st series	6 th Issue – 2 nd Series	6 th Issue – 3 rd series	7 th Issue – 1 st series	7 th Issue – 2 nd series	Consolidated
2024	200,000	-	-	-	-	-	-	200,000
2025	-	100,000	250,000	-	-	-	-	350,000
2026	-	100,000	-	375,000	-	-	-	475,000
2027	-	100,000	-	-	-	350,000	-	450,000
2028	-	-	-	-	375,000	-	-	375,000
2029	-	-	-	-	-	-	350,000	350,000
Total	200,000	300,000	250,000	375,000	375,000	350,000	350,000	2,200,000

Covenants

The debentures are subject to financial covenants, and their maturity may be accelerated in the event the Company fails to comply with the following financial ratio:

- Net financial debt/EBITDA ratio lower than or equal to 3.0 times.

As of September 30, 2023, the Fleury Group was following financial ratios and other covenants.

The other information referring to this Note did not undergo significant changes in relation to that disclosed in Note 15 - Debentures, of the financial statements for the year ended December 31, 2022.

16. Leases

As of September 30, 2023, the lease liabilities are as follows:

a) Minimum lease payments:

	Parent Company		Consolidated	
	09/30/2023	12/31/2022	09/30/2023	12/31/2022
≤01 year	253,822	236,287	382,534	266,798
>01 year	1,267,038	1,333,021	1,691,260	1,446,972
	1,520,860	1,569,308	2,073,794	1,713,770
(-) Future financial charges	(530,325)	(559,707)	(643,198)	(595,521)
Present value of minimum payments	990,535	1,009,601	1,430,596	1,118,249
Current	168,787	153,133	263,101	174,901
Non-current	821,748	856,468	1,167,495	943,348

The maturity dates of non-current installments as of September 30, 2023 are stated as follows:

	Parent Company	Consolidated
2024	186,547	344,370
2025	223,358	305,741
>2026	411,843	517,384
Total	821,748	1,167,495

We show below the changes in lease:

	Parent Company	Consolidated
Balance at 12/31/2022	1,009,601	1,118,249
Business combination (a)	-	366,747
Addition	100,942	118,046
Realization of adjustment to present value	73,492	92,970
Inflation adjustment	15,047	43,181
Write-off	(39,386)	(44,656)
Amortization of interest	(73,492)	(84,798)
Amortization of principal	(118,671)	(179,143)
Merger of companies	23,002	-
Balance at 09/30/2023	990,535	1,430,596

(a) Refers to the acquisition of Hermes Pardini and Retina (pursuant to Note 3) and remeasurement of net assets from the acquisition of Methodos.

As of September 30, 2023, the Company has an operating lease balance of R\$ 13,996 linked to financial institutions, allocated in the Lease account, referring to computer equipment used to support the administrative areas.

17. Suppliers

	Parent Company		Consolidated	
	09/30/2023	12/31/2022	09/30/2023	12/31/2022
Direct material and test intermediation	82,081	86,065	225,307	130,072
Medical services	61,533	60,634	114,556	76,854
Real estate and utilities	37,670	37,072	62,726	38,665
Outsourced services	15,114	25,635	49,656	35,175
Overhead	15,054	12,279	41,944	17,685
Suppliers of property, plant and equipment - CapEx	29,506	46,531	36,517	46,541
IT and telecommunications	17,636	8,212	26,902	10,060
Institutional and legal matters	4,127	4,438	10,918	5,850
Marketing	4,888	2,678	6,699	3,366
Total	267,609	283,544	575,225	364,268

18. Labor obligations

	Parent Company		Consolidated	
	09/30/2023	12/31/2022	09/30/2023	12/31/2022
Provision for vacation and social security charges	83,044	73,629	141,945	85,845
Provision for 13 th salary payable and charges	43,947	-	74,420	-
Provision for profit sharing	42,249	51,083	64,134	52,548
Salaries and social security charges payable	22,130	28,144	41,584	36,924
Commission and Bonus	23,478	28,570	26,350	28,701
Provision for health care	19,837	17,528	20,247	17,530
Loans to employees	1,147	1,150	2,270	1,200
Other	1,916	4,471	9,811	4,852
Total	237,748	204,575	380,761	227,600

19. Tax liabilities

	Parent Company		Consolidated	
	09/30/2023	12/31/2022	09/30/2023	12/31/2022
ISS on turnover	18,417	12,787	37,021	21,832
REFIS installment plan - Law 11941	5,918	7,125	24,631	15,390
PIS/COFINS on Billing	2,025	809	9,205	3,053
PIS, COFINS, CSRF	2,597	2,617	4,283	3,218
Withholding income tax (IRRF)	1,267	1,380	2,334	1,785
Withholding INSS	880	1,819	1,096	2,006
Other	1,212	825	3,056	2,236
Total	32,316	27,362	81,626	49,520
Current	30,663	23,338	68,007	40,812
Non-current	1,653	4,024	13,619	8,708

As of September 30, 2023, the non-current portion matured as follows:

	Consolidated
2024	2,365
2025	3,188
>2026	8,066
Total	13,619

20. Accounts payable – Acquisition of companies

Relate to debts assumed for acquisition of companies, to be settled as provided for in the contracts, updated monthly mainly based on IGP-M FGV and IPCA IBGE. The balances are recorded at present value and therefore may differ from the amounts highlighted in the acquisition documents.

	Parent Company		Consolidated	
	09/30/2023	12/31/2022	09/30/2023	12/31/2022
SAHA	-	-	98,025	111,720
IACS	-	-	94,887	-
Marcelo Magalhães	35,754	33,080	35,754	33,080
Vita	-	-	27,794	35,158
Lafe	-	-	24,651	35,830
Diagmax	18,907	18,133	18,907	18,133
LPA	-	-	16,193	-
CIP	15,367	13,979	15,367	13,979
Moacir	-	-	11,527	12,237
CSV	-	-	10,310	-
Bioclinico	-	-	10,269	7,281
Psychemedics	-	-	9,041	-
Pretti	-	-	8,440	9,738
APC	-	-	8,117	-
Inlab	7,866	7,156	7,866	7,156
Retina	-	-	7,764	-
HSB	-	-	7,375	-
Other (a)	9,093	16,080	27,653	32,351
Total	86,987	88,428	439,940	316,663
Current	10,064	24,786	64,769	40,337
Non-current	76,923	63,642	375,171	276,326

(a) Of the amount described in these lines, R\$ 15,323 are withheld from the sellers as an Escrow deposit.

As of September 30, 2023, the non-current portion matured as follows:

	Consolidated
2024	18,738
2025	55,748
2026	57,955
>2026	242,730
Total	375,171

21. Other liabilities

	Parent Company		Consolidated	
	09/30/2023	12/31/2022	09/30/2023	12/31/2022
Advance from clients	-	-	14,718	3,664
Other accounts payable (a)	9,354	8,141	9,974	10,999
Prepaid Revenue (Bradesco Payroll)	1,390	5,119	1,390	5,119
Employee reimbursements	634	391	635	393
Deferred revenue	-	-	240	369
Total	11,378	13,651	26,957	20,544
Current	11,378	13,651	26,957	17,969
Non-current	-	-	-	2,575

(a) Substantially refers to balances payable to operators.

22. Current and deferred income tax and social contribution

a) Breakdown

	Parent Company			Consolidated		
	Balance sheet		Income (loss)	Balance sheet		Income (loss)
	09/30/2023	12/31/2022	09/30/2023	09/30/2023	12/31/2022	09/30/2023
Lease operation	34,255	31,248	3,007	45,705	31,999	13,706
Tax loss	-	-	-	44,832	63,315	(18,483)
Linearization of effective rate	38,343	-	38,343	42,117	-	42,117
Provision for tax, labor and civil risks	15,082	17,232	(2,150)	21,879	18,301	3,578
Provision for profit sharing	14,365	17,368	(3,003)	21,578	17,742	3,836
Provisions Labor	12,494	11,444	1,050	19,857	12,014	7,843
Net assets acquired in a business combination	17,411	1,076	16,335	16,629	294	16,335
Derivative instrument - Swap	-	-	-	12,690	-	12,690
Estimated losses from disallowances and default	5,274	4,391	883	11,380	4,980	6,400
Update – Accounts payable – acquisition of companies	4,475	2,111	2,364	10,597	5,363	5,234
Stock option plan	7,932	9,818	(1,886)	7,932	9,818	(1,886)
Realization of gain/loss	(129,495)	(1,494)	(128,001)	(172,962)	(38,833)	(134,129)
Effects of goodwill amortization for tax purposes	(472,906)	(459,417)	(13,489)	(599,694)	(474,117)	(125,577)
Other	21	8	13	(2,743)	159	(2,902)
Deferred tax assets (liabilities), net	(452,749)	(366,215)	(86,534)	(520,203)	(348,965)	(171,238)

Reflected on the balance sheet as follows:

Opening balance	(366,215)	-	-	(348,965)	-	-
Tax revenue /(expenses) recognized in income (loss)	49,001	-	-	23,219	-	-
Changes in equity not affecting income (loss)	(135,535)	-	-	(194,457)	-	-
Deferred tax assets (liabilities), net	(452,749)	-	-	(520,203)	-	-

	Consolidated								
	Fleury	CIP	CPMA	IRN	CPC	Santecorp Holding	Saúde iD	Vita Clínicas	IHP
Assets (a)	180,933	795	26,546	763	1,687	23,656	1,072	1,721	48,286
Liabilities	(633,682)	(720)	(62,818)	-	-	-	-	-	(108,442)
Net effect	(452,749)	75	(36,272)	763	1,687	23,656	1,072	1,721	(60,156)

(a) The balance of Fleury S.A, CPMA, CIP and Hermes Pardini is presented net.

In the Consolidated, deferred tax assets are expected to be realized as follows:

	Consolidated
2023	63,592
2024	93,724
2025	33,191
2026	26,326
>2027	68,626
Total	285,459

b) Income tax and social contribution on net income, current and deferred, in income (loss) are reconciled as follows:

	Parent Company		Consolidated	
	09/30/2023	09/30/2022	09/30/2023	09/30/2022
Income before income tax (IRPJ) and social contribution (CSLL)	350,189	372,821	438,299	375,270
(x) Combined rate	34%	34%	34%	34%
(=) IRPJ and CSLL expense	(119,064)	(126,759)	(149,022)	(127,592)
Linearization effect of the effective rate	38,343	28,744	42,117	28,744
Interest on own capital	31,460	-	31,460	-
Effect of Companies taxed under the deemed income regime	-	-	4,798	10,702
Equity in net income of subsidiaries	38,811	11,697	147	226
Write-off of deferred tax	-	-	(28,830)	-
Other permanent additions (exclusions), net	2,739	(9,547)	713	(8,916)
Income tax and social contribution expense	(7,711)	(95,865)	(98,617)	(96,836)
Current	(56,712)	(122,675)	(121,836)	(140,817)
Deferred	49,001	26,810	23,219	43,981
Effective rate - %	2.20%	25.71%	22.50%	25.80%

23. Provision for tax, labor, civil risks

a) Breakdown of the balance

	Parent Company		Consolidated	
	09/30/2023	12/31/2022	09/30/2023	12/31/2022
Tax	18,891	21,465	35,808	26,640
Labor	20,438	24,790	24,995	26,829
Civil	5,029	4,428	22,772	9,738
Subtotal	44,358	50,683	83,575	63,207
Formation of loss (a)	-	-	67,416	-
Judicial deposits (lawsuits involving probable losses)	(34,772)	(34,120)	(35,946)	(34,120)
Total	9,586	16,563	115,045	29,087
Judicial Deposits (non-current assets)	(17,995)	(17,764)	(25,461)	(24,160)

b) Changes – Consolidated

	Balance at 12/31/2022	Addition/ Reversal (b)	Formation of loss (a)	Business combination	Reclassifications / Payments	Inflation adjustment	Balance at 09/30/2023
Labor	26,829	(949)	1,952	2,911	(2,969)	(827)	26,947
Tax	26,640	195	56,196	11,283	(2,117)	(194)	92,003
Civil	9,738	(5,866)	9,268	2,349	19,373	(2,821)	32,041
Subtotal	63,207	(6,620)	67,416	16,543	14,287	(3,842)	150,991
Judicial deposits (lawsuits involving probable losses)	(34,120)	-	-	(1,469)	(357)	-	(35,946)
Total	29,087	(6,620)	67,416	15,074	13,930	(3,842)	115,045

(a) Loss measured in the business combination with Hermes Pardini from lawsuits with likelihood of possible loss, see Note 3.

(b) The change observed in the statement of cash flows takes into account the amounts included in this column.

c) Lawsuits classified as probable losses, for which no provision is set up:

The provisioning criteria for indicating a probable loss follow the assessment guidelines defined in the company's internal policies, with the occurrence of a conviction being an important factor for such an analysis. Provisioning is monitored by advisory services and adjustments are made according to the occurrence of acts in the course of the proceeding that may change the established provisioning criteria.

Tax

The Company has tax proceedings totaling R\$35,808, of which the tax matter is the challenge of the unconstitutionality of Law 11001/2001, which introduced ICMS (state VAT) on imports in the state of São Paulo. This law was enacted after Constitutional Amendment 33/2001 and before Supplementary Law 114/2002, therefore failing to comply with the legislative procedure required for the collection of the ICMS levied on import transactions carried out in the state of São Paulo. However, considering a statement with general repercussion issued by the Federal Supreme Court, which established that Law 11001/2001 was constitutional, the Company set up a provision to cover the related risks totaling R\$ 16,499 as of September 30, 2023 (R\$ 16,916 as of December 31, 2022).

We also have lawsuits arising from the acquired company Instituto Hermes Pardini S.A., whose filing officer is the Federal Revenue Office in Belo Horizonte/Minas Gerais, due to decision-making orders that partially approved IRPJ and CSLL offsets declared in PER/DCOMPs for the years 2011 to 2022, whose proof of withholding tax was not located and presented in the Administrative proceeding with provision on September 30, 2023 in the amount of R\$ 11,972 (R\$ 5,242 as of December 31, 2022).

Labor

In the labor sphere, the Company has lawsuits classified as a probable loss on September 30 totaling R\$ 24,995 (R\$ 26,695 as of December 31, 2022), which (i) R\$ 22,599 (R\$ 24,005 as of December 31, 2022) refers to lawsuits (such as labor claims from former employees, class actions, annulment actions); (ii) R\$ 900 (R\$ 859 as of December 31, 2022) refer to joint liability lawsuits filed by employees of companies that provide specialized services to the Company on an outsourced basis and (iii) ongoing administrative proceedings, totaling R\$ 228 (R\$ 102 as of December 31, 2022).

Civil

In the civil sphere, the Company is party to lawsuits classified as probable losses totaling R\$ 22,772 as of September 30, 2023 (R\$ 9,738 as of December 31, 2022). Civil proceedings provisioned as a probable loss are those in which there is evidence that corroborates the probable occurrence of disbursement by the Company. Such proceedings are based, for the most part, in demands in which possible failures are discussed. The provisioning criteria for indicating a probable loss follow the assessment guidelines defined in the company's internal policies, with the occurrence of a conviction being an important factor for such an analysis. Provisioning is monitored by advisory services and adjustments are made according to the occurrence of acts in the course of the proceeding that may change the established provisioning criteria.

d) Lawsuits classified as possible loss

The Company has tax, civil and labor claims which are not provisioned, since they involve risk of loss classified by management and by its legal advisors as possible.

As of September 30, 2023, the consolidated amount was approximately R\$ 735,302 (R\$ 525,218 as of December 31, 2022).

The tax matters classified as possible losses amounted to R\$ 377,744 (R\$ 285,352 as of December 31, 2022). At the federal level, these matters were comprised substantially of: (i) R\$ 194,470 (R\$ 174,745 as of December 31, 2022), which mainly refer to discussions involving the non-mandatory payment of federal taxes (IRPJ, CSLL, PIS and COFINS), the most representative being a claim in the amount of R\$ 27,496 referring to the Annulment Suit filed for the waiving of the tax credit arising from an administrative proceeding filed in 2012 aiming at the collection of IRPJ, CSLL, PIS and COFINS launched by arbitration of revenues from the company NKB (merged by Fleury S.A. in August 2009). We also have the amount of R\$ 43,323 from lawsuits of the companies acquired by Fleury S.A. in 2011, (ii) social security contributions, totaling R\$ 58,151 (R\$ 27,872 as of December 31, 2022), and (iii) federal lawsuits of a different nature, totaling R\$ 14,960 (R\$ 10,118 as of December 31, 2022).

At the state level, the law lawsuits classified as possible losses totaled R\$ 9,511 (R\$ 9,002 as of December 31, 2022) and related mainly to the challenge of ICMS levied on equipment imports.

With respect to discussions of municipal taxes, the lawsuits classified as possible losses amounted to R\$ 98,866 (R\$ 63,615 as of December 31, 2022) and related mainly to cases involving the Tax on Services of any Nature (ISSQN).

At the civil level, the Company has lawsuits classified as possible loss totaling R\$ 109,087 (R\$ 34,125 as of December 31, 2022), of which R\$ 45,171 (R\$ 16,724 as of December 31, 2022) related mainly to civil liability lawsuits with claims for property damages and mental distress arising, among other reasons, from alleged diagnostic error or procedural failure, and other lawsuits involving different claims totaling R\$ 63,916 (R\$ 17,402 as of December 31, 2022).

As of September 30, 2023, labor lawsuits classified as possible loss total R\$ 248,471 (R\$ 205,741 as of December 31, 2022) of which (i) R\$ 230,229 (R\$ 192,626 as of December 31, 2022) refer to lawsuits (such as labor claims of former employees, relief from judgment, public civil lawsuits, annulment and tax enforcement actions, enforcement action); (ii) R\$ 18,121 (R\$ 12,857 as of December 31, 2022) refer to joint liability lawsuits filed by employees of companies that provide specialized services to the Company on an outsourced basis and (iii) ongoing administrative proceedings, totaling R\$ 121 (R\$ 258 as of December 31, 2022).

In the labor scope, the Company was summoned in a Public Civil Action (ACP) in process before the Labor Court of São Paulo, which pleads the conviction due to failure to meet the legal quota of disabled employees. The Company, in its defense, proved that it made all possible efforts to comply with the legal provision, and the failure to meet the quota is due to facts beyond the company's control, and there is favorable case law of the Supreme Labor Court. To confirm this thesis, the lower court dismissed the ACP. The Labor Public Prosecutor's Office filed an Ordinary Appeal addressed to the Regional Labor Court of the 2nd Region, which is awaiting judgment.

The Company was summoned in a Public Civil Action (ACP) pending before the Labor Courts of São Paulo, in which the Public Labor Ministry (MPT) pleads for Fleury's conviction due to the alleged noncompliance with rules related to workers' health and safety. The Company presented its defense proving the regularity of the requests made in the dispute. The company is awaiting the pre-trial discovery proceedings and trial.

24. Related parties

Impacts on statement of income and balance sheet

a) Breakdown of balances

Companies	Nature of the operation	Parent Company					
		Assets		Liabilities		Income (loss) - Revenue/(expense)	
		09/30/2023	12/31/2022	09/30/2023	12/31/2022	09/30/2023	09/30/2022
Companhia Brasileira de Soluções e Serviços - Visa Vale	Service provider - Benefits (Meal Voucher)	-	-	-	466	-	(76,180)
Bradesco Vida e Previdência S.A.	Service Provider - Benefits (Private pension)	-	-	-	-	(4,682)	(4,681)
Bradesco Saúde S.A.	Service provider - Benefits (Healthcare plan – Employees)	-	-	-	-	(95,505)	(89,160)
Banco Bradesco S.A.	Sale of payroll and financial transactions	370,502	865,911	1,390	5,119	48,483	32,963
Transinc Fundo de Investimento Imobiliário - FII	Rental provider - Property lease classified under CPC 06	5,863	32,747	7,860	38,043	(1,468)	(8,786)
Harmonikos Participações e Empreendimentos Ltda.	Rental provider - Property lease classified under CPC 06	9,545	10,657	11,020	13,019	(3,268)	(2,832)
Amicabilis Participações e Empreendimentos Ltda.	Rental provider - Property lease classified under CPC 06	14,157	14,087	16,980	17,336	(4,874)	(3,348)
BSP Empreendimentos Imobiliários Ltda.	Rental provider - Property lease classified under CPC 06	195,363	202,793	202,336	204,670	(25,404)	-
OdontoPrev S.A.	Service provider - Benefits (Odontological plan – Employees)	-	-	-	-	(2,675)	(2,692)
CM Médicos Associados Ltda.	Service provider - Rendering of medical services	-	-	-	-	(1,436)	(1,438)
CPC Ltda	Processing of exams - Clinical Analysis	-	-	-	-	1,049	793
Fleury CPMA S.A.	Processing of exams and transfer of benefits (Healthcare plan)	422	286	-	-	9,961	7,855
DIAGMAX Ltda	Processing of exams - Clinical Analysis	-	-	-	-	-	641
INLAB Ltda	Processing of exams - Clinical Analysis	-	-	-	-	-	1,730
IRN Ltda	Processing of exams - Clinical Analysis	-	-	-	-	-	24
Metodos Laboratorio, Analises Clinicas e Hematologia LTDA.	Processing of exams - Clinical Analysis	-	-	-	-	795	-
Instituto Hermes Pardini S.A.	Processing of exams - Clinical Analysis	-	-	-	-	1,039	-
Laboratório Pretti Ltda	Processing of exams - Clinical Analysis	-	-	-	-	2,343	1,517
Laboratório Bioclínico Ltda.	Processing of exams - Clinical Analysis	-	-	-	-	1,435	1,052
Saude iD	Transfer of benefits (Healthcare plan – Employees)	634	-	-	-	634	-
Instituto Hermes Pardini S/A	Transfer of benefits (Healthcare plan – Employees)	62	-	-	-	62	-
Santecorp Holding Ltda.	Sublease and transfer of benefits (Healthcare plan – Employees)	627	152	-	-	627	583
	Sublease and expense reimbursement (labor of dedicated employees)	186	219	-	-	186	-
Clinica de olhos Dr. Moacir Cunha S.A.							
Fleury Centro de Procedimentos Medicos Avançados S.A.	Sublease	392	-	-	-	392	-
Vita Clinicas Medicina Especializada LTDA.	Sublease	45	-	-	-	45	-
CIP - Centro de Infusões Pacaembu LTDA	Expense reimbursement (labor of dedicated employees)	169	161	-	-	169	-
Vita Clinicas Medicina Especializada LTDA.	Expense reimbursement (labor of dedicated employees)	169	161	-	-	169	-
Laboratório Marcelo Magalhães S.A.	Expense reimbursement (labor of dedicated employees)	15	-	-	-	15	-
Moacir Instituto de Oftalmologia 9 de Julho - Serviços Médico S.A.	Expense reimbursement (labor of dedicated employees)	94	-	-	-	94	-
Instituto de Oftalmologia 9 de Julho - Serviços Médico S.A.	Expense reimbursement (labor of dedicated employees)	75	-	-	-	75	-
Clinica Oftalmológica São Lucas Ltda. - Retina Clinic	Expense reimbursement (labor of dedicated employees)	75	-	-	-	75	-
Saha Centro de Infusões Ltda.	Expense reimbursement (labor of dedicated employees)	169	-	-	-	169	-
		598,564	1,127,174	239,586	278,653	(71,495)	(141,959)

Companies	Nature of the operation	Consolidated					
		Assets		Liabilities		Income (loss) - Revenue/(expense)	
		09/30/2023	12/31/2022	09/30/2023	12/31/2022	09/30/2023	09/30/2022
Companhia Brasileira de Soluções e Serviços - Visa Vale	Service provider - Benefits (Meal Voucher)	-	-	53	590	(95,474)	(80,442)
Bradesco Vida e Previdência S.A.	Service Provider - Benefits (Private pension)	-	-	-	1	(4,744)	(4,736)
Bradesco Saúde S.A.	Service provider - Benefits (Healthcare plan - Employees)	-	-	-	-	(95,864)	(89,339)
Banco Bradesco S.A.	Sale of payroll and financial transactions	611,531	980,246	16,286	8,822	64,946	39,190
OdontoPrev S.A.	Service provider - Benefits (Odontological plan - Employees)	-	-	-	-	(2,779)	(2,794)
CM Médicos Associados Ltda.	Service provider - Rendering of medical services	-	-	149	-	(1,436)	(1,438)
Transinc Fundo de Investimento Imobiliário - FII.	Rental provider - Property lease classified under CPC 06	5,863	32,747	7,860	38,043	(1,468)	(8,786)
Harmonikos Participações e Empreendimentos Ltda.	Rental provider - Property lease classified under CPC 06	9,545	10,657	11,020	13,019	(3,268)	(2,832)
Amicabilis Participações e Empreendimentos Ltda.	Rental provider - Property lease classified under CPC 06	14,157	14,087	16,980	17,336	(4,874)	(3,348)
BSP Empreendimentos Imobiliários Ltda.	Rental provider - Property lease classified under CPC 06	195,363	202,793	202,336	204,670	(25,404)	-
AP Imobiliária Ltda.	Rental provider - Property lease classified under CPC 06	15,126	-	17,692	-	(1,755)	-
Azevedo e Dias Administração Patrimonial Ltda.	Rental provider - Property lease classified under CPC 06	5,785	-	6,319	-	(1,071)	-
Bitoliz Consultoria de imóvel Ltda.	Rental provider - Property lease classified under CPC 06	2,401	-	2,573	-	(214)	-
Dumont Empreendimentos Imobiliários Ltda.	Rental provider - Property lease classified under CPC 06	3,893	-	4,886	-	(417)	-
Empreendimentos Imobiliários Vista Alegre Ltda	Rental provider - Property lease classified under CPC 06	46,413	-	54,159	-	(5,364)	-
Paes e Alcantara Serviços Ltda.	Rental provider - Property lease classified under CPC 06	9,432	-	10,087	-	(838)	-
Villa de Migliori Participações Ltda.	Rental provider - Property lease classified under CPC 06	23,058	-	23,417	-	(1,859)	-
		942,567	1,240,530	373,817	282,481	(181,883)	(154,525)

Banco Bradesco, a shareholder with an indirect ownership interest in the Company, holds a stake and/or control in companies and health plan operators with commercial relationship with the Fleury group, which are among the largest clients. The impact on the consolidated statement of income (gross revenue) from these clients represented 11% as of September 30, 2023 (19% as of September 30, 2022).

The Company signed an Association Agreement for the creation of a new company (JV Oncologia), in partnership with Atlântica Hospitais e Participações S.A., an indirect subsidiary of Banco Bradesco S.A. and Real e Benemerita Associação Portuguesa de Beneficência. No active and passive operations were identified, except as shown in Note 11.

b) Directors' fees and Board's remuneration

The remuneration of directors and members of Management was approved at Meeting held on April 28, 2023 and are calculated in "General and administrative expenses" caption in the statement of income.

	Parent Company	
	09/30/2023	09/30/2022
Directors' fees and Board's remuneration		
Managers	19,963	17,018
Salaries, social charges and benefits	7,222	6,587
Bonus and profit sharing	7,760	5,561
Share-based payments	4,843	4,740
Post-employment benefits	138	130
Board of Directors		
Salaries, social charges and benefits	7,944	8,333
Total	27,907	25,351

As established by CPC 33 - Employee benefits, the Company grants post-employment benefits to its administrators, consisting of private pension and life insurance.

Fleury Group remunerates its employees through profit sharing, according to the performance verified during the year versus the established goals. This remuneration is recognized as a liability and profit-sharing expense, based on a methodology that considers the estimated achievement of these goals.

The provision for profit sharing, which includes employees and administrators, totaled R\$ 65,724 in the period ended September 30, 2023 (R\$ 43,855 as of September 30, 2022).

25. Shareholders' equity

a) Capital

The capital as of September 30, 2023, fully paid-up, is R\$ 2,762,950, represented by 547,191,026 common, registered, book-entry shares with no par value. The net amount of expenses with share issues is R\$ 2,736,029.

During the meeting held on August 18, 2022, the Company was authorized to increase its capital, regardless of statutory reform, upon resolution of the Board of Directors up to the limit of R\$ 4,000,000,000 (four billion reais) in common shares.

Changes in the period:

We show below the changes in capital during the period:

	Number of shares	Total amount
Balance at 12/31/2022	367,197,096	1,743,823
Exercise of stock options (Note 26b)	12,696	111
Shares issued in business combination – Note 3 (ii)	153,924,773	849,016
Issue for bonus (i)	26,056,461	170,000
Balance at 09/30/2023	547,191,026	2,762,950

i) Stock bonus

On September 6, 2023, the Board of Directors of Fleury S.A. approved the increase in the Company's capital through the capitalization of part of the investment reserves with the issue and distribution of shares, which were allocated free of charge as a bonus at the rate of 1 new share for every 20 shares issued by the Company.

ii) Capital reserve and equity valuation adjustments

Due to the consummation of the business combination with Hermes Pardini and the capital increase upon replacement of shares, 153,924,773 new common shares were issued for the total subscription price of R\$ 2,234,987.

Of this total, an amount of R\$ 849,016 was allocated to the capital account, R\$ 1,312,087 was allocated to the Company's capital reserve, and R\$ 73,884 was allocated to equity valuation adjustments.

b) Treasury shares

At a meeting of the Board of Directors held on November 26, 2020, the Company's Buyback Program was approved, without reducing the capital, and up to 3,035,263 common shares may be acquired up to 3,035,263 common shares.

The purpose of the Program is to buy back shares to back the Company's Deferred Stock Plan (as Note 26), approved at the Extraordinary Shareholders' Meeting on 12/05/2019, and they may also be held in treasury, disposed of or canceled.

We present below the changes in treasury shares as of September 30, 2023:

	Number of shares	Average share price, net of fees and brokerage	Total amount
Balance at 12/31/2022	793,123	25.18	19,971
Changes occurred in the 1Q23	(426,479)	25.23	(10,758)
Share bonus - Note 25 (i)	18,332	-	-
Balance at 09/30/2023	384,976	23.93	9,213

c) Investment reserve

At the Annual and Extraordinary Shareholders' Meeting held on April 28, 2023, the allocation of the Company's income (loss) for 2022 was approved, and the amount of R\$ 162,453 were retained, pursuant to art. 196 of Law 6404/1976 and the capital budget, previously approved by the Board of Directors, and allocated to the profit retention reserve for investments. This retention is in line with the Company's plan to invest in new technologies and new businesses. On June 6, 2023, R\$ 170,000 was allocated to increase the Company's capital, through capitalization, with the issue and distribution of shares.

d) Interest on own capital

As of August 30, 2023, the Company approved the payment of interest on own capital to shareholders in the amount of R\$ 92,530,000, corresponding to the gross amount per share of R\$ 0.1692 for the year 2023 and the payment was made on October 31, 2023.

	Approval date	Payment date	Gross amount	Net value
JCP 3Q23	08/30/2023	10/31/2023	92,530	78,650

26. Employee benefits

a) Private pension

The Company is a sponsor of the supplementary pension entity named and currently managed by Bradesco Vida e Previdência S.A. and Sul América S.A., which mainly aims at supplementing the government pension benefits. Said plan is a defined contribution plan and during the period ended September 30, 2023 the Company made contributions in the amount of R\$ 1,924 (R\$ 1,461 as of September 30, 2022), recorded in "Costs of services provided" and "General and Administrative Expenses".

b) Share-based remuneration

Fleury Group offers cash and share-based remuneration plans to executives, according to which the Company receives services from employees as consideration of the purchase and stock options granted. Granted options fair values determined on grant date are recorded under straight-line method as expenses in income (loss) for the year during the period in which the right is acquired.

We demonstrate below the movement for the period:

		Grant date		
		2016	2018	
		July 2023	May 2023	June 2023
Balance at 12/31/2022	Options	12,696	328,125	41,125
	Average exercise price	8.74	27.66	26.24
Prescribed		-	7,500	-
Expired	Options	12,696	93,750	11,750
Balance at 09/30/2023	Options	-	226,875	29,375

As of September 30, 2023, the market value of each share was R\$ 15.15 (R\$ 16.30 as of September 30, 2022).

Options granted from 2016 to 2018: were priced based on the “Black & Scholes” model, and the significant data included in the pricing model for the fair value of the stock options granted in this period were:

	Vesting in 48 months – Grant on		
	Grant as of 08/01/2022	Grant as of 08/30/2021	Grant as of 11/26/2020
Volatility	28.36%	29.49%	38.19%
Dividend Yield	1.75%	3.22%	4.80%
Expected life for the year	2 years	2 years	4 years
Risk-free annual interest rate	12.70%	7.59%	4.78%

(i) New Long-Term Incentive Plan - Deferred Stock

The Plan sets forth the general conditions for the grant of shares issued by the Company to its employees or to those other companies under its control, duly selected by the Board of Directors. The plan provides for the transfer of shares to the members of the Executive Board, subject to the amounts set forth by the conditions of the deferred share grant agreement.

As of September 30, 2023, the Company recognized a “pro-rata” expense in the amount of R\$ 10,184 in General Administrative Expenses referring to the Deferred Stock Option plan (R\$ 9,320 as of September 30, 2022).

New 2023 program

On August 10, 2023, the Company’s 2023 Deferred Share Program was approved at a meeting of the Board of Directors, and the first granting of this program, within the scope of the Deferred Share Plan, was approved at the Extraordinary General Meeting held on December 05, 2019.

The program provides for the issue of up to 1,282,393 (one million, two hundred eighty-two thousand, three hundred and ninety-three) Deferred Shares, and up to 576,040 (five hundred seventy-six thousand and forty) Extraordinary Shares. The plan’s vesting period will be 4 years and it will be divided into 4 annual installments (20%/20%/20%/40%), i.e., each year the title to a proportion of the granted shares will be transferred.

As of September 30, 2023, the Company recognized a “pro-rata” expense in the amount of R\$ 10,184 in General Administrative Expenses referring to the Deferred Stock Option plan (R\$ 9,320 as of September 30, 2022).

	Vesting in 48 months			
	Grant as of 08/10/2023	Grant as of 08/01/2022	Grant as of 08/30/2021	Grant as of 11/26/2020
Volatility	24.60%	38.76%	31.61%	38.19%
Dividend Yield	4.80%	4.80%	4.80%	4.80%
Expected life for the year	4 years	4 years	4 years	4 years
Risk-free annual interest rate	4.78%	4.78%	4.78%	4.78%

The other information referring to this Note did not undergo significant changes in relation to that disclosed in Note 26 - Employee benefits, of the financial statements for the year ended December 31, 2022.

27. Revenue from rendering of services

a) Breakdown of balances

Parent Company

	Three-month period ended September 30,		Nine-month period ended September 30,	
	2023	2022	2023	2022
Gross revenue	1,135,343	1,020,387	3,298,142	3,029,315
Taxes	(69,395)	(62,368)	(201,900)	(184,580)
Disallowances	(10,493)	(9,431)	(30,625)	(28,386)
Rebates	(2,227)	(820)	(5,011)	(1,678)
Net revenue	1,053,228	947,768	3,060,606	2,814,671

Consolidated

	Three-month period ended September 30,		Nine-month period ended September 30,	
	2023	2022	2023	2022
Gross revenue	2,011,020	1,234,207	5,125,951	3,603,996
Taxes	(123,963)	(75,620)	(314,949)	(221,341)
Disallowances	(13,546)	(10,546)	(36,695)	(31,335)
Rebates	(3,466)	(1,407)	(7,898)	(3,027)
Net revenue	1,870,045	1,146,634	4,766,409	3,348,293

The breakdown of net sales between the main lines of the Company's services (Diagnostic Medicine, Integrated Medicine), is presented in Note 34 - Segment Information.

The other information referring to this Note did not undergo significant changes in relation to that disclosed in Note 27 - Revenue from services rendered as of December 31, 2022.

28. Cost of services rendered

Parent Company

	Three-month period ended September 30,		Nine-month period ended September 30,	
	2023	2022	2023	2022
Medical personnel and services	(351,878)	(322,209)	(1,048,692)	(928,711)
Direct material and test intermediation	(124,854)	(121,443)	(363,880)	(374,835)
Rentals, services with occupancy and utilities	(145,538)	(134,347)	(426,738)	(399,985)
Depreciation and amortization	(96,019)	(86,692)	(282,681)	(254,469)
Overhead	(2,034)	(1,669)	(6,254)	(5,573)
Total	(720,323)	(666,360)	(2,128,245)	(1,963,573)

Consolidated

	Three-month period ended September 30,		Nine-month period ended September 30,	
	2023	2022	2023	2022
Medical personnel and services	(583,227)	(387,841)	(1,527,076)	(1,133,944)
Direct material and test intermediation	(377,693)	(171,595)	(906,302)	(507,718)
Rentals, services with occupancy and utilities	(233,578)	(150,945)	(606,132)	(450,425)
Depreciation and amortization	(144,412)	(99,150)	(377,394)	(289,676)
Overhead	(3,570)	(2,032)	(10,170)	(6,354)
Total	(1,342,480)	(811,563)	(3,427,074)	(2,388,117)

29. General and administrative expenses**Parent Company**

	Three-month period ended September 30,		Nine-month period ended September 30,	
	2023	2022	2023	2022
Personnel and benefits	(66,698)	(57,231)	(200,539)	(164,373)
Depreciation and amortization	(17,624)	(9,809)	(59,332)	(35,056)
Institutional and legal matters (a)	(3,208)	(4,472)	(66,110)	(13,238)
IT and telecommunications (a)	(3,700)	(2,527)	(12,559)	(6,694)
Real estate and utilities	(3,034)	(4,646)	(13,718)	(12,630)
Outsourced services	(3,631)	(2,929)	(9,929)	(8,792)
Other general and administrative expenses	(6,809)	(6,593)	(22,486)	(15,424)
Total	(104,704)	(88,207)	(384,673)	(256,207)

Consolidated

	Three-month period ended September 30,		Nine-month period ended September 30,	
	2023	2022	2023	2022
Personnel and benefits	(82,717)	(71,589)	(248,517)	(205,060)
Depreciation and amortization	(43,749)	(10,603)	(108,105)	(41,379)
Institutional and legal matters (a)	(7,754)	(6,050)	(77,521)	(17,633)
IT and telecommunications (a)	(16,930)	(5,204)	(34,816)	(13,184)
Real estate and utilities	(7,179)	(5,029)	(21,066)	(14,299)
Outsourced services	(7,347)	(3,915)	(17,259)	(11,135)
Other general and administrative expenses	(3,229)	(8,329)	(15,307)	(18,983)
Total	(168,905)	(110,719)	(522,591)	(321,673)

(a) The increase is related to non-recurring expenses incurred in the business combination, as mentioned in this quarter's Management Report available on the Investor Relations website.

30. Commercial expenses

The amounts presented below are mainly due to the Hermes Pardini operation, which significantly increased the Company's Lab-to-Lab business and, consequently, commercial efforts with partner laboratories.

	Parent Company			
	Three-month period ended September 30,		Nine-month period ended September 30,	
	2023	2022	2023	2022
Personnel and benefits	(2,207)	(1,913)	(7,340)	(5,909)
Marketing	(7,052)	(5,841)	(19,633)	(18,096)
Other sales	(367)	(298)	(987)	(935)
Total	(9,626)	(8,052)	(27,960)	(24,940)

	Consolidated			
	Three-month period ended September 30,		Nine-month period ended September 30,	
	2023	2022	2023	2022
Personnel and benefits	(20,701)	(1,993)	(37,055)	(6,174)
Marketing	(13,653)	(8,575)	(32,913)	(25,370)
Other sales	(8,358)	(303)	(14,757)	(987)
Total	(42,712)	(10,871)	(84,725)	(32,531)

31. Other operating revenues (expenses), net

	Parent Company			
	Three-month period ended September 30,		Nine-month period ended September 30,	
	2023	2022	2023	2022
Provision/losses with defaulted parties	(797)	(317)	(1,263)	(2,425)
Reversal (provision) for tax, labor and civil risks	271	(970)	(422)	(4,281)
Income (loss) in write-off/sale of assets	2,745	213	1,723	724
Other revenues (expenses)	(2,563)	8,743	(5,451)	22,217
Total	(344)	7,669	(5,413)	16,235

Consolidated

	Three-month period ended September 30,		Nine-month period ended September 30,	
	2023	2022	2023	2022
Provision/losses with defaulted parties	(4,456)	(389)	(6,395)	(2,685)
Reversal (provision) for tax, labor and civil risks	(6,048)	(1,269)	(6,620)	(4,600)
Income (loss) in write-off/sale of assets	2,807	413	2,128	900
Other revenues (expenses)	9,552	10,456	8,691	26,386
Total	1,855	9,211	(2,196)	20,001

32. Financial income (loss)**a) Breakdown of financial results****Parent Company**

	Three-month period ended September 30,		Nine-month period ended September 30	
	2023	2022	2023	2022
Financial revenues:				
Yield from interest earning bank deposits – Securities	19,590	22,419	82,731	55,971
Exchange-rate change	35	139	143	441
PIS and COFINS on financial revenue	(987)	(1,122)	(4,143)	(2,641)
Other	1,709	1,906	6,328	4,708
Total	20,347	23,342	85,059	58,479
Financial expenses:				
Interest on debentures	(79,849)	(95,938)	(250,182)	(226,544)
Lease interest	(24,349)	(18,088)	(73,492)	(54,143)
Derivative financial instruments	79	5	(864)	(1,477)
Exchange-rate change	(103)	(271)	(270)	(828)
Inflation adjustment of taxes and accounts payable	(1,983)	(2,625)	(7,683)	(6,606)
Interest on financing and other interest	(9)	(198)	(124)	(4,821)
Inflation adjustment of contingencies	1,159	(1,583)	(1,503)	(4,491)
Other	(1,639)	(3,045)	(5,774)	(7,337)
Total	(106,694)	(121,743)	(339,892)	(306,247)
Net financial income (loss)	(86,347)	(98,401)	(254,833)	(247,768)

	Consolidated			
	Three-month period ended September 30,		Nine-month period ended September 30,	
	2023	2022	2023	2022
Financial revenues:				
Yield from interest earning bank deposits – Securities	28,924	25,484	97,462	63,224
Exchange-rate change (a)	7,078	145	25,734	448
Derivative financial instruments	19,145	-	19,145	-
Yield from interest earning bank deposits	3,096	2,167	16,093	3,798
PIS/COFINS on financial revenues	(1,485)	(1,303)	(5,473)	(3,013)
Other	4,094	2,461	11,777	6,169
Total	60,852	28,954	164,738	70,626
Financial expenses:				
Interest on debentures	(79,849)	(95,938)	(250,182)	(226,544)
Lease interest	(34,153)	(21,080)	(92,970)	(61,152)
Derivative financial instruments	(8,071)	5	(30,535)	(1,477)
Exchange-rate change	(24,057)	(272)	(27,545)	(829)
Inflation adjustment of taxes and accounts payable	(6,771)	(5,321)	(25,127)	(13,508)
Interest on financing and other interest	(4,979)	(367)	(10,695)	(5,078)
Inflation adjustment of contingencies	(677)	(1,703)	(3,842)	(4,805)
Other	(5,201)	(3,689)	(15,797)	(8,601)
Total	(163,758)	(128,365)	(456,693)	(321,994)
Net financial income (loss)	(102,906)	(99,411)	(291,955)	(251,368)

(a) In the Consolidated, mainly arising from the working capital loan, see Note 14.

33. Earnings per share

Basic earnings per share

Basic earnings per share is calculated by dividing profit attributable to company shareholders by the weighted average number of common shares issued during the period.

	Parent Company	
	09/30/2023	09/30/2022
Income attributable to Company's controlling shareholders	342,478	276,956
Weighted average number of common shares outstanding (-) treasury shares	484,571,727	317,134,752
Basic earnings per share – R\$	0.71	0.87

Diluted earnings per share

Diluted profit per share is calculated by adjusting the weighted average number of common shares, presuming the conversion of all the potential diluted common shares. The Company had potential diluting common shares outstanding during the period, according to the Company's Stock Option Plan, as follows:

	Parent Company	
	09/30/2023	09/30/2022
Income attributable to Company's controlling shareholders	342,478	276,956
Weighted average number of common shares outstanding (-) treasury shares	484,571,727	317,134,752
(+) Adjustment by stock options	47,986	146,696
(=) Weighted average of number of common shares for diluted earnings per share	484,619,713	317,281,448

Diluted earnings per share - R\$

0.71

0.87

34. Information per business segment

As of September 30, 2023, the Fleury Group's Management conducts analyses based on two reportable business segments: Diagnostic Medicine and Integrated Medicine. It included the Dental segment up to February 2023. The segments presented in the financial statements are strategic business units that offer different products and services. The operation acquired from Hermes Pardini mainly includes laboratory analysis and medical imaging (Diagnostic Medicine) and Lab-to-Lab (Integrated Medicine).

	Period ended 09/30/2023		
	Diagnostic medicine	Integrated Medicine	Consolidated
Net revenue	3,415,257	1,351,152	4,766,409
EBITDA	1,085,589	129,733	1,215,322
Equity in net income of subsidiaries	-	431	431
Depreciation and amortization	-	-	(485,499)
Financial income (loss)	-	-	(291,955)
EBIT			438,299

	Period ended 09/30/2022			
	Diagnostic medicine	Integrated Medicine	Dental	Consolidated
Net revenue	2,642,306	705,987	-	3,348,293
EBITDA	913,816	43,212	-	957,028
Equity in net income of subsidiaries	-	-	665	665
Depreciation and amortization	-	-	-	(331,055)
Financial income (loss)	-	-	-	(251,368)
EBIT	-	-	-	375,270

35. Insurance coverage

The Company takes out insurance coverage on a global basis for possible risks related to its assets, loss of profits and/or liabilities in amounts sufficient to cover possible claims, considering the nature of its activities and in accordance with the assessment of Management and its specialized consultants. The full premium of the consolidated insurance policies in effect as of September 30, 2023 is R\$ 5,280.

The contracts are effective until April 12, 2024.

The maximum insured amount of the main insurance coverages, as of September 30, 2023, is as follows:

	Consolidated
Operating risks	1,087,622
Civil liability, including cyber risks	138,500
International transport – Imports - US\$	3,150

36. Subsequent event

Issue of Debentures

On October 13, 2023, the Company approved the 8th issue of simple debentures, non-convertible into shares, of the unsecured kind, in a single series ("Debentures"), for public distribution according to the automatic registration procedure ("Offer"), exclusively for professional investors, under the terms of CVM Resolution 160, dated July 13, 2022.

The funds raised on 10/24/2023 will be used for general corporate use, such as strengthening working capital and/or extending the Company's liabilities.

The main terms and conditions of the Offer are summarized below:

Series	Amount	Term	Rate	Interest	Amortization
Single	R\$ 500 million	5 years	DI + 1.23%	Semi-annual	Annual (4 th and 5 th year)

Jeane Tsutsui
CEO

José Antônio de Almeida Filippo
Chief Financial, Legal and Investor Relations Officer

Gisele Schneider
Accountant
CRC 1SP304488

Certificate Of Completion

Envelope Id: 96CBCAA87681425888D64500D577BB49

Status: Completed

Subject: Complete with DocuSign: ITR 3T23- Inglês.pdf

LoS / Área: Assurance (Audit, CMAAS)

Tipo de Documento: Relatórios ou Deliverables

Source Envelope:

Document Pages: 69

Signatures: 1

Envelope Originator:

Certificate Pages: 2

Initials: 0

Jose Ribeiro

AutoNav: Enabled

Av. Francisco Matarazzo, 1400, Torre Torino, Água Branca

Enveloped Stamping: Enabled

São Paulo, SP 05001-100

Time Zone: (UTC-03:00) Brasilia

jose.ribeiro@pwc.com

IP Address: 134.238.160.188

Record Tracking

Status: Original

10 November 2023 | 11:54

Holder: Jose Ribeiro

jose.ribeiro@pwc.com

Location: DocuSign

Status: Original

10 November 2023 | 13:54

Holder: CEDOC Brasil

BR_Sao-Paulo-Arquivo-Atendimento-Team@pwc.com

Location: DocuSign

Signer Events

Marcelo Orlando

marcelo.orlando@pwc.com

partner

PwC BR

Security Level: Email, Account Authentication (None), Digital Certificate

Signature Provider Details:

Signature Type: ICP Smart Card

Signature Issuer: AC SERASA RFB v5

Electronic Record and Signature Disclosure:

Not Offered via DocuSign

Signature

DocuSigned by:
Marcelo Orlando
EFC9BAA8A6A1420...

Signature Adoption: Pre-selected Style

Using IP Address: 201.56.164.188

Timestamp

Sent: 10 November 2023 | 12:08

Viewed: 10 November 2023 | 13:53

Signed: 10 November 2023 | 13:53

In Person Signer Events**Signature****Timestamp****Editor Delivery Events****Status****Timestamp****Agent Delivery Events****Status****Timestamp****Intermediary Delivery Events****Status****Timestamp****Certified Delivery Events****Status****Timestamp****Carbon Copy Events****Status****Timestamp**

Giulianna Rossi

giulianna.rossi@pwc.com

PwC BR

Security Level: Email, Account Authentication (None)

Electronic Record and Signature Disclosure:

Not Offered via DocuSign

COPIED

Sent: 10 November 2023 | 12:08

Carbon Copy Events	Status	Timestamp
Jose Ribeiro jose.ribeiro@pwc.com Security Level: Email, Account Authentication (None) Electronic Record and Signature Disclosure: Not Offered via DocuSign	<div>COPIED</div>	Sent: 10 November 2023 13:54 Viewed: 10 November 2023 13:54 Signed: 10 November 2023 13:54

Witness Events	Signature	Timestamp
----------------	-----------	-----------

Notary Events	Signature	Timestamp
---------------	-----------	-----------

Envelope Summary Events	Status	Timestamps
Envelope Sent	Hashed/Encrypted	10 November 2023 12:08
Certified Delivered	Security Checked	10 November 2023 13:53
Signing Complete	Security Checked	10 November 2023 13:53
Completed	Security Checked	10 November 2023 13:54

Payment Events	Status	Timestamps
----------------	--------	------------